Brainsway Overview
BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology aims to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. The company's flagship technology is based on deep transcranial magnetic stimulation, aimed at helping smokers quit (FDA cleared since August 2020). BrainsWay's technology is based on patents filed by the US National Institutes of Health (NIH) and by the company. The company holds an exclusive license from the NIH for the patent and its technology. BrainsWay is FDA cleared for treating adult patients with major depressive disorder who have failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. BrainsWay is also approved in Canada for the treatment of major depressive disorder. It is also FDA cleared as an intended adjunct treatment for adult patients with obsessive-compulsive disorder. Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease. BrainsWay collaborates with scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.
Cumulative Funding Raised Over Time ($)
$4.3MApr 2012
$12.8MDec 2017
$24.6MMar 2014
$44.6MSep 2024
Latest News
growth-positive
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, announced it will report its third quarter 2025 financial results on November 11, 2025. The company will host a conference call and webcast to discuss these results and provide updates on business operations. BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) platform has received FDA clearance for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company continues to conduct clinical trials for additional indications. Founded in 2003, BrainsWay operates in the U.S. and Israel, focusing on increasing global awareness and access to its Deep TMS technology.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway Ltd. has experienced significant stock growth, with shares rising 11.3% over the past month and reaching a 52-week high. The company has consistently surpassed earnings expectations, reporting a recent EPS of $0.1 against a $0.07 estimate. For the current fiscal year, Brainsway is projected to achieve a 94.44% increase in EPS and a 24.5% rise in revenues. Despite its strong performance, the stocks valuation metrics suggest it trades at a premium compared to industry averages. Brainsways Zacks Rank of #2 (Buy) and its VGM Score of B indicate positive growth prospects, although its value score is moderate.
growth-positive
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, announced strategic investments in two U.S. mental health providers, including a $1.5 million initial investment in Heading Health, with potential for an additional $2.5 million. This move is part of BrainsWays strategy to enhance patient access to Deep TMS Therapy and drive long-term shareholder value. The company has completed four strategic minority investments in 2025, aiming to expand its commercial partnerships while maintaining its focus on scientific and technological advancements. BrainsWays Deep TMS platform is FDA-cleared for multiple indications, and the company is conducting further clinical trials.
InvestmentPartners
growth-positive
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
The article discusses the performance of Alkermes (ALKS) within the Medical sector, highlighting its strong year-to-date performance compared to its peers. Alkermes is part of the Medical - Biomedical and Genetics industry and holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. The companys full-year earnings estimate has increased by 15.4% over the past 90 days, reflecting improving analyst sentiment. Despite slightly underperforming its industry group, Alkermes has outperformed the broader Medical sector, which has gained about 1.7% on average. The article also mentions Brainsway Ltd. Sponsored ADR, another strong performer in the Medical sector.
growth-positive
Do Options Traders Know Something About Brainsway Stock We Don't?
The article discusses the recent high implied volatility in the options market for Brainsway Ltd., indicating that investors expect significant stock movement. Brainsway, a company in the Medical - Products industry, currently holds a Zacks Rank #3 (Hold). Over the past 60 days, analyst estimates for the companys current quarter have increased, suggesting a positive outlook. The high implied volatility could present trading opportunities, as options traders may sell premium to capture decay. The article also highlights Zacks Investment Researchs approach to identifying profitable trades.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $79.95M |
| Last funding | $20M |
| Stage | Public |
| Rounds | 6 |
| Investors | 6 |
Team Members
8
Employees: 51-200
Web & Social Links
| Website | www.brainsway.com |
Locations
Hartom Street 19, Jerusalem, Israel
Burlington, MA, USA
Photos & Videos
3 item(s)
Brainsway Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
—Tags (16)
neuro-stimulationchronic-painnon-invasivepsychiatryneurologymental-healthmedical-devicesparkinsonalzheimers-diseasebrain-disorderhospitalsclinicshealthcare-providersmedical-technologiestreatmentspatientsGeographic Markets
GlobalBrainsway Financials
$79.95M
Total funding
Undisclosed
Capital raised
$20M
Last funding
Public
Funding stage
6
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$4.3MApr 2012
$12.8MDec 2017
$24.6MMar 2014
$44.6MSep 2024
Private Equity Funding
PIPE
Sep 2024
$20M
Valor Equity Partners (Lead)
PIPE
Dec 2017
$8.5M
IBI Investment House, Noked Capital, Phoenix Insurance
PIPE
Mar 2014
$11.8M
Yelin Lapidot Investment House
PIPE
Apr 2012
$4.3M
Shavit Capital Fund
Public Offering / Exit
POEvent
Apr 2019
Undisclosed
POEvent
Jan 2007
Undisclosed
Brainsway Lifecycle
Cumulative Funding Raised Over Time
$4.3MApr 2012
$12.8MDec 2017
$24.6MMar 2014
$44.6MSep 2024
All Events
PIPE
Sep 2024
$20M
Valor Equity Partners (Lead)
PIPE
Dec 2017
$8.5M
IBI Investment House, Noked Capital, Phoenix Insurance
PIPE
Mar 2014
$11.8M
Yelin Lapidot Investment House
PIPE
Apr 2012
$4.3M
Shavit Capital Fund
POEvent
Apr 2019
Undisclosed
POEvent
Jan 2007
Undisclosed
Brainsway News
202 articles
growth-positive
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, announced it will report its third quarter 2025 financial results on November 11, 2025. The company will host a conference call and webcast to discuss these results and provide updates on business operations. BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) platform has received FDA clearance for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company continues to conduct clinical trials for additional indications. Founded in 2003, BrainsWay operates in the U.S. and Israel, focusing on increasing global awareness and access to its Deep TMS technology.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway Ltd. has experienced significant stock growth, with shares rising 11.3% over the past month and reaching a 52-week high. The company has consistently surpassed earnings expectations, reporting a recent EPS of $0.1 against a $0.07 estimate. For the current fiscal year, Brainsway is projected to achieve a 94.44% increase in EPS and a 24.5% rise in revenues. Despite its strong performance, the stocks valuation metrics suggest it trades at a premium compared to industry averages. Brainsways Zacks Rank of #2 (Buy) and its VGM Score of B indicate positive growth prospects, although its value score is moderate.
growth-positive
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, announced strategic investments in two U.S. mental health providers, including a $1.5 million initial investment in Heading Health, with potential for an additional $2.5 million. This move is part of BrainsWays strategy to enhance patient access to Deep TMS Therapy and drive long-term shareholder value. The company has completed four strategic minority investments in 2025, aiming to expand its commercial partnerships while maintaining its focus on scientific and technological advancements. BrainsWays Deep TMS platform is FDA-cleared for multiple indications, and the company is conducting further clinical trials.
InvestmentPartners
growth-positive
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
The article discusses the performance of Alkermes (ALKS) within the Medical sector, highlighting its strong year-to-date performance compared to its peers. Alkermes is part of the Medical - Biomedical and Genetics industry and holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. The companys full-year earnings estimate has increased by 15.4% over the past 90 days, reflecting improving analyst sentiment. Despite slightly underperforming its industry group, Alkermes has outperformed the broader Medical sector, which has gained about 1.7% on average. The article also mentions Brainsway Ltd. Sponsored ADR, another strong performer in the Medical sector.
growth-positive
Do Options Traders Know Something About Brainsway Stock We Don't?
The article discusses the recent high implied volatility in the options market for Brainsway Ltd., indicating that investors expect significant stock movement. Brainsway, a company in the Medical - Products industry, currently holds a Zacks Rank #3 (Hold). Over the past 60 days, analyst estimates for the companys current quarter have increased, suggesting a positive outlook. The high implied volatility could present trading opportunities, as options traders may sell premium to capture decay. The article also highlights Zacks Investment Researchs approach to identifying profitable trades.
growth-positive
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay Ltd. has received FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (TMS) system, aimed at treating major depressive disorder. This approval is expected to improve patient access and provider flexibility, potentially increasing adoption due to fewer required visits. The companys shares rose by 11.9% following the announcement, and it has seen a 79.2% increase year-to-date. The new protocol, which shortens treatment time significantly, is supported by clinical data showing comparable outcomes to the standard approach. BrainsWay is preparing for provider training and reimbursement updates, positioning this development as a significant growth opportunity in the mental health market.
FDA approved/pending approval
growth-positive
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
BrainsWay Ltd. has received FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (Deep TMS) system for major depressive disorder (MDD), including those with comorbid anxiety symptoms. This new protocol reduces the treatment duration significantly, requiring only 6 days of treatment compared to the previous 4 weeks. The clearance is based on a multicenter study showing comparable efficacy to the standard protocol. The accelerated protocol is now commercially available in the U.S., expanding access for patients and providers. BrainsWay plans to provide training to healthcare providers and seek updates to reimbursement policies to facilitate patient adoption.
Product StageFDA approved/pending approval
growth-positive
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
BrainsWay Ltd. has made a strategic $5 million investment in Neurolief Ltd., a company developing wearable neuromodulation devices for mental health treatment. This investment allows BrainsWay to expand into the at-home treatment market, complementing its existing Deep TMS platform. Neuroliefs Proliv Rx, designed for Major Depressive Disorder, is pending FDA approval. The investment includes a convertible loan with additional funding contingent on FDA approval and revenue milestones. BrainsWays shares have increased following the announcement, reflecting positive market reception. The collaboration aims to diversify revenue streams and strengthen BrainsWays position in the mental health treatment market.
InvestmentPartnersProduct Stage
growth-positive
Neurolief Prepares for Launch of its Proliv™Rx System for Major Depressive Disorder with Strategic Investment from BrainsWay
Neurolief, a company specializing in non-invasive neuromodulation therapies, has received a strategic investment from BrainsWay Ltd., a leader in neurostimulation treatments. This investment is a significant milestone as Neurolief awaits FDA approval for its Proliv™Rx product, designed to treat Major Depressive Disorder (MDD). The partnership aims to expand access to innovative mental health treatments. Neuroliefs technology offers a new approach to treating MDD, providing at-home therapy options for patients who do not respond to traditional treatments. The collaboration with BrainsWay, which has a global reach with its Deep TMS system, positions Neurolief to scale effectively post-FDA approval.
InvestmentPartnersFDA approved/pending approval
growth-positive
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, has made a strategic investment in Neurolief Ltd. through a $5 million convertible loan with an option to acquire the company. Neurolief is known for its wearable, non-invasive brain neuromodulation platform designed for home use. This investment aligns with BrainsWays goal to expand its market reach by offering mental health treatments outside traditional clinical settings. Neuroliefs Proliv™Rx device, pending FDA approval, could become the first FDA-cleared device for treating Major Depressive Disorder (MDD) outside of clinics. The partnership aims to leverage BrainsWays commercial platform and explore synergies between the two companies.
InvestmentPartners
growth-positive
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, announced a strategic equity financing agreement with Axis Management Company, Inc. BrainsWay will invest $2.3 million initially, with a potential additional $1 million based on milestones, to acquire a minority stake in Axis. This investment is part of BrainsWays strategy to expand access to innovative mental health treatments and support healthcare providers in their growth. The partnership aims to enhance Axiss clinical services and expand its reach, leveraging BrainsWays Deep TMS technology. This collaboration is expected to accelerate growth and improve patient outcomes.
InvestmentPartners
growth-positive
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
Phibro Animal Health (PAHC) has experienced a significant increase in its stock price, rising 9% over the past month and reaching a new 52-week high of $32.08. The company has consistently exceeded earnings expectations, with a recent EPS of $0.63 against a consensus estimate of $0.52. For the current fiscal year, Phibro is projected to post earnings of $2.3 per share on $1.28 billion in revenues, with further growth expected in the next fiscal year. The companys stock is considered a strong value investment, with a Zacks Rank of #2 (Buy) and a VGM Score of A. Despite its recent high, Phibros valuation metrics suggest potential for further gains.
growth-positive
Are Medical Stocks Lagging Biotricity (BTCY) This Year?
Biotricity Inc., a company in the Medical sector, has shown impressive performance with a year-to-date gain of about 115.6%, outperforming its sector peers, which have lost about 3.3% on average. The company, which belongs to the Medical Info Systems industry, is currently ranked #2 (Buy) by Zacks Rank, indicating a strong earnings outlook. Over the past three months, the Zacks Consensus Estimate for Biotricitys full-year earnings has increased by 17.9%, reflecting improved analyst sentiment. Another company in the sector, Brainsway Ltd., has also performed well with a year-to-date return of 57.5%. Both companies are recommended for investors interested in the Medical sector.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
Brainsway Ltd. has seen a significant increase in its stock value, with shares rising 22.8% over the past month and reaching a new 52-week high. The company has consistently outperformed earnings expectations, with a recent earnings report showing an EPS of $0.1 against a consensus estimate of $0.07. For the current fiscal year, Brainsway is expected to post an EPS of $0.34 on $50.88 million in revenues, representing significant growth from the previous year. The companys stock is currently trading at a premium compared to its industry peers, but it holds a favorable Zacks Rank of #2 (Buy) and a strong VGM Score of A, indicating potential for continued growth.
growth-positive
Wall Street Analysts Think Brainsway (BWAY) Could Surge 25.58%: Read This Before Placing a Bet
Shares of Brainsway Ltd. (BWAY) have increased by 7.4% over the past four weeks, closing at $12.98. Analysts predict a potential upside, with a mean price target of $16.3, indicating a 25.6% increase. The lowest estimate suggests a 9.4% rise, while the highest predicts a 46.4% surge. Despite the positive consensus, the reliability of price targets is questioned due to potential biases and business incentives. Analysts agree on better-than-expected earnings, which could further boost the stock. The article highlights the importance of considering multiple factors beyond price targets for investment decisions.
growth-positive
Surging Earnings Estimates Signal Upside for Brainsway (BWAY) Stock
Brainsway Ltd. is experiencing a positive trend in its earnings estimates, leading to a growth-positive outlook for the company. Analysts have revised their earnings estimates upwards, which is expected to positively impact the companys stock price. The company is currently ranked #2 (Buy) by Zacks Rank, indicating strong earnings growth prospects. Over the past month, the consensus estimate for the companys earnings has increased significantly, with no negative revisions. This has resulted in a 7.4% increase in the companys stock price over the past four weeks, suggesting investor confidence in its future performance.
growth-positive
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
BrainsWay reported a record quarterly revenue of $12.6 million for Q2 2025, marking a 26% increase from Q2 2024. The company achieved an operating profit of $0.6 million and an adjusted EBITDA of $1.5 million. BrainsWay raised its full-year 2025 revenue and EBITDA guidance, with remaining performance obligations increasing by 25% year-over-year to $62 million. The company shipped 88 Deep TMS systems in Q2 2025, increasing its total installed base to 1,522 systems. BrainsWay entered an equity financing transaction with Stella MSO, LLC and is partnering with Valor Equity Partners to identify additional clinical targets. The company submitted data to the FDA for an accelerated Deep TMS treatment protocol and is working with Israels Ministry of Defense on PTSD treatment qualifications.
CustomersPartnersInvestment
growth-positive
BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
BrainsWay, a leader in noninvasive neurostimulation treatments, announced the launch of two new Continuing Medical Education (CME) courses to enhance clinician knowledge of Transcranial Magnetic Stimulation (TMS). These courses, supported by independent educational grants from BrainsWay, aim to deepen understanding of TMS and its application in treating mental health disorders. The courses are led by experts in psychiatry and brain stimulation and offer practical guidance for integrating TMS into clinical practice. BrainsWays Deep TMS™ technology is FDA-cleared for various indications, including depression and OCD. This initiative reflects BrainsWays commitment to advancing brain stimulation and supporting healthcare providers.
growth-positive
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, announced it will report its Q2 2025 financial results on August 13, 2025. The company will host a conference call to discuss these results and provide updates on business operations. BrainsWay is known for its Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which has received FDA clearance for multiple indications, including major depressive disorder, OCD, and smoking addiction. The company is conducting additional clinical trials for various psychiatric and neurological disorders. Founded in 2003, BrainsWay operates in the US and Israel and is committed to expanding global access to its technology.
growth-positive
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
The article discusses the importance of net profit margin as a key indicator of a companys financial health and operational efficiency. Companies like Catalyst Pharmaceuticals, Inc., Gambling.com Group Limited, Orion Group Holdings, Inc., and BrainsWay Ltd. are highlighted for their strong net profit margins, which provide them with a competitive edge. A high net profit margin is essential for attracting investors and skilled employees, ultimately enhancing business value. However, the article notes that net profit margin varies across industries and may not be as critical for technology companies. The article also emphasizes the importance of solid EPS growth alongside a healthy net profit margin for a robust business model.
growth-positive
Here's What Could Help Brainsway (BWAY) Maintain Its Recent Price Strength
The article discusses the potential of Brainsway Ltd. Sponsored ADR (BWAY) as a profitable investment for trend investors. The stock has shown a solid price increase of 55.7% over the past 12 weeks and 10.6% over the past four weeks, indicating a strong upward trend. BWAY is trading at 81.5% of its 52-week high-low range, suggesting a potential breakout. The stock carries a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by earnings estimate revisions and EPS surprises. The article emphasizes the importance of sound fundamentals and positive earnings estimates in maintaining stock momentum.
growth-negative
Is the Options Market Predicting a Spike in Brainsway Stock?
The article discusses the recent high implied volatility in the options market for Brainsway Ltd., particularly for the Jan 16, 2026 $12.50 Call. This suggests that investors expect significant movement in the stock price, potentially due to an upcoming event. Brainsway is currently ranked as a Zacks Rank #3 (Hold) in the Medical - Products Industry, which is in the bottom 34% of the Zacks Industry Rank. Analysts have slightly increased their earnings estimates for the current quarter. The high implied volatility could indicate a trading opportunity, as options traders might sell premium to capture decay, hoping the stock doesnt move as much as expected.
growth-positive
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
Brainsway Ltd. experienced a 5.3% increase in its stock price, closing at $11.49, driven by positive market sentiment following successful clinical trial results for its Deep TMS therapy in treating Major Depressive Disorder (MDD). The study showed significant improvements in depression symptoms, enhancing investor confidence in the technologys market potential. The company is expected to report quarterly earnings of $0.04 per share, with revenues projected to rise by 23.8% from the previous year. The consensus EPS estimate has been revised 10% higher over the last 30 days, indicating potential for further stock price appreciation.
Product Stage
growth-positive
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 30.98%: Here's is How to Trade
Shares of Brainsway Ltd. (BWAY) have risen by 7.1% over the past four weeks, closing at $11.49. Analysts have set a mean price target of $15.05, suggesting a potential upside of 31%. The price targets range from $14.20 to $16.00, with a standard deviation of $0.74, indicating strong agreement among analysts. Despite skepticism about the reliability of price targets, the consensus among analysts about Brainsways potential to exceed earnings expectations suggests a positive outlook. Analysts price targets are often influenced by business incentives, but a low standard deviation in targets indicates a high degree of agreement on the stocks potential movement.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway Ltd. Sponsored ADR has experienced a significant increase in its stock price, reaching a new 52-week high of $12, with a 14.2% rise over the past month. The company has consistently surpassed earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0.02 in its last earnings report. For the current fiscal year, Brainsway is expected to post earnings of $0.15 per share on $50.36 million in revenues, with a projected increase in both EPS and revenues for the next fiscal year. Despite its high valuation metrics, the company holds a Zacks Rank of #2 (Buy) due to favorable earnings estimate revisions.
growth-positive
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced positive preliminary results from a multicenter, randomized controlled trial on accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for treating major depressive disorder (MDD). The trial, involving 104 patients across eight sites, demonstrated that the accelerated protocol, which requires fewer clinic visits, achieved comparable efficacy to the standard protocol. Key findings include significant improvements in depression scores, high response and remission rates, shorter session durations, and a faster median time to remission. The accelerated protocol was well-tolerated, with mild side effects and no serious adverse events reported. This advancement could significantly reduce the treatment burden for patients with MDD.
Product Stage
growth-positive
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced its Gold Sponsorship of the Clinical TMS Society’s 2025 Annual Meeting. The company will showcase its Deep Transcranial Magnetic Stimulation (Deep TMS) technology, featuring live demonstrations and new research. A key session will present preliminary results from a multicenter trial comparing standard and accelerated Deep TMS depression protocols. Additional research includes studies on smoking cessation and adolescent depression using Deep TMS. BrainsWay is the first TMS company with three FDA-cleared indications, including major depressive disorder, OCD, and smoking addiction. The company continues to advance its technology through ongoing clinical trials.
Product StageFDA approved/pending approval
growth-positive
Does Brainsway (BWAY) Have the Potential to Rally 43.88% as Wall Street Analysts Expect?
Brainsway Ltd. (BWAY) has experienced a 20.1% increase in its stock price over the past four weeks, closing at $10.46. Analysts have set a mean price target of $15.05, suggesting a potential 43.9% upside. The price targets range from $14.20 to $16, with a standard deviation of $0.74, indicating strong agreement among analysts. Despite skepticism about the reliability of price targets, the consensus among analysts about Brainsways potential to exceed earnings expectations supports a positive outlook. The article highlights the importance of considering multiple factors beyond price targets when making investment decisions.
growth-positive
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders, has entered into a strategic equity financing agreement with Stella MSO, LLC. The agreement involves a $5 million investment in Stella, granting BrainsWay a minority stake in the company. This investment is part of BrainsWays broader strategy to expand access to innovative mental health treatments and support the interventional psychiatry space. The partnership aims to leverage Stellas clinical excellence and operational strength to enhance patient care. BrainsWays Deep TMS technology is FDA-cleared for multiple indications, and the company continues to conduct clinical trials to expand its applications.
InvestmentPartners
growth-positive
Earnings Estimates Moving Higher for Brainsway (BWAY): Time to Buy?
Brainsway Ltd. (BWAY) is experiencing a positive trend in earnings outlook, with analysts raising their earnings estimates for the company. This optimism is reflected in the companys stock performance, which has increased by 23.4% over the past four weeks. The Zacks Rank system, which evaluates stocks based on earnings estimate revisions, has assigned Brainsway a rank of #2 (Buy), indicating strong potential for further growth. The companys earnings estimate for the current quarter remains unchanged from the previous year, while the full-year estimate shows a decrease. Despite this, the overall trend in estimate revisions is encouraging, suggesting that Brainsway could be a solid investment choice.
growth-positive
Wall Street Analysts See a 41.31% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Brainsway Ltd. (BWAY) has seen a significant increase in its stock price, closing at $10.65 with a 35.5% gain over the past four weeks. Analysts have set a mean price target of $15.05, indicating a potential 41.3% upside. The price targets range from $14.20 to $16, with a standard deviation of $0.74, showing a high level of agreement among analysts. Despite skepticism about the reliability of price targets, the consensus suggests potential growth, supported by expected better-than-estimated earnings. Analysts optimism may be influenced by business incentives, but the tight clustering of targets could guide further research into the stocks potential.
growth-positive
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
BrainsWay reported record quarterly sales of $11.5 million in Q1 2025, marking a 27% increase compared to Q1 2024. The company shipped a net total of 81 Deep TMS systems, a 42% increase from the previous year, indicating strong demand. Operating profit rose by 519% to $0.6 million, and Adjusted EBITDA increased by 81% to $1.3 million. The company is progressing in its U.S. clinical trial for an accelerated Deep TMS treatment protocol for major depressive disorder and is working with Israels Ministry of Defense on PTSD treatments. BrainsWay reiterated its full-year 2025 financial guidance, projecting revenue between $49 million to $51 million.
CustomersProduct Stage
growth-positive
BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, is participating in the American Psychiatric Association (APA) Annual Meeting from May 17-21, 2025, in Los Angeles. The company will host a master course on integrating novel treatments into psychiatric practice and showcase its Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is FDA-cleared for treating several mental health disorders. BrainsWays involvement highlights its expanding role in psychiatric care and commitment to advancing mental health treatments. The company is conducting additional clinical trials to explore further applications of Deep TMS.
Product StageFDA approved/pending approval
growth-positive
BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025
BrainsWay, a leader in noninvasive neurostimulation treatments, announced it will report its Q1 2025 financial results on May 13, 2025. The company will host a conference call to discuss these results and provide business updates. BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) platform has received FDA clearance for multiple indications, including major depressive disorder, OCD, and smoking addiction. The company is conducting additional clinical trials to expand its treatment applications. Founded in 2003, BrainsWay operates in Israel and the U.S., focusing on increasing global awareness and access to its Deep TMS technology.
growth-positive
Steris Stock Gets Relative Strength Rating Lift
Steris has received a Relative Strength Rating upgrade, indicating an improvement in its technical stock performance. This upgrade suggests a positive outlook for the companys stock, although it remains to be seen if this trend will continue. The article does not mention any specific events or changes within the company, such as acquisitions, partnerships, or management changes, that might have contributed to this upgrade. The focus is primarily on the stocks performance in the market.
growth-positive
BrainsWay Ltd (BRSYF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
BrainsWay Ltd reported a 27% year-over-year increase in revenue for Q4 2024, reaching $11.4 million, and a 29% increase for the full year 2024. The company shipped 75 Deep TMS systems in Q4 2024, marking a 25% increase compared to the previous year. The company achieved a strong gross margin of 75% and generated positive net income for the fifth consecutive quarter. Despite increased research and development expenses, BrainsWay Ltd anticipates 20% to 24% revenue growth in 2025. The company faces challenges in expanding reimbursement coverage for OCD treatment in the US and is not actively pursuing acquisitions, which may limit external growth opportunities.
growth-positive
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
BrainsWay reported a strong financial performance for Q4 and the full year 2024, with record quarterly sales of $11.4 million and a 29% year-over-year revenue increase to $41 million. The company achieved significant milestones, including a $20 million strategic equity financing transaction with Valor Equity Partners and expanded FDA labeling for its Deep TMS system. BrainsWay is advancing its clinical trials and expanding its market presence, notably entering the Canadian market through an exclusive distribution agreement and increasing its reach in East Asia. The company expects continued growth in 2025, projecting revenues between $49 million and $51 million.
Product StageInvestmentFDA approved/pending approvalPartnersCustomers
growth-positive
BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 18, 2025. The company will present its advancements in Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, which has received FDA clearance for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is conducting additional clinical trials for various psychiatric and neurological disorders. The presentation will be available via live webcast and archived on the companys website. BrainsWay aims to increase global awareness and access to its Deep TMS technology.
growth-positive
BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?
BrainsWay has experienced a recent decline in stock price, falling below its 50-day moving average, which may indicate a technical resistance at its IPO level. Despite this, the company is expected to show significant year-over-year growth in sales and earnings per share. BrainsWay is expanding its global presence with new system placements in Taiwan and South Korea and has made a significant expansion in the U.S. market with a large order for its Deep TMS systems. The company received a $20 million investment from Valor Equity Partners to enhance market awareness and data analysis. Additionally, Israels Ministry of Defense approved reimbursement for Deep TMS therapy for PTSD patients.
CustomersInvestmentExpand
growth-positive
BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
BrainsWay, a leader in noninvasive neurostimulation treatments, will announce its Q4 and full-year 2024 financial results on March 11, 2025. The company will host a conference call to discuss these results and provide business updates. BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) platform has received FDA clearance for three indications, including major depressive disorder, OCD, and smoking addiction. The company is conducting additional clinical trials for various psychiatric and neurological disorders. Founded in 2003, BrainsWay operates in Israel and the U.S., focusing on expanding global access to its Deep TMS technology.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
Brainsway Ltd. Sponsored ADR (BWAY) has seen its stock rise by 10.5% over the past month, reaching a new 52-week high of $11.5. The company has consistently surpassed earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0.01 in its last earnings report. For the current fiscal year, Brainsway is projected to earn $0.16 per share on $40.41 million in revenues, with expectations of $0.21 per share on $46.38 million in revenues for the next fiscal year. Despite its high valuation, the stock is rated as a strong buy due to rising earnings estimates and a favorable Zacks Rank and Style Scores.
growth-positive
Outbrain (OB) and Brainsway (BWAY) Are Aggressive Growth Stocks
The article discusses two aggressive growth stock picks by Brian Bolan from Zacks Investment Research: Outbrain and Brainsway. Both companies are highlighted as Zacks Rank #1 (Strong Buy) stocks. Outbrain, a recommendation engine, connects advertisers with consumers and has been part of the Stocks Under $10 service. Brainsway, in the medical products space, offers Transcranial Magnetic Stimulation technology for treating major depressive disorder and obsessive-compulsive disorder. The article emphasizes the growth and value scores of these companies, suggesting a positive outlook for potential investors.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Soars to 52-Week High, Time to Cash Out?
Brainsway Ltd. Sponsored ADR has experienced significant stock growth, with shares rising 18.2% over the past month and reaching a new 52-week high. The company has consistently surpassed earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0.01 in its latest earnings report. For the current fiscal year, Brainsway is projected to earn $0.16 per share on $40.41 million in revenues, with further growth expected next year. Despite its high valuation, the company maintains a strong Zacks Rank of #1 (Strong Buy) due to favorable earnings revisions. The stocks growth and momentum scores are high, though its value score is lower, indicating a premium valuation compared to peers.
growth-positive
Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?
Brainsway Ltd. (BWAY) shares rose by 8% in the last trading session, driven by positive market sentiment due to the companys strong financial performance and promising growth prospects. The company reported a 26% year-over-year revenue growth in Q3 and positive clinical trial outcomes for its Deep TMS therapy, boosting investor confidence. The consensus EPS estimate for the upcoming quarter has been revised 250% higher, indicating potential continued growth in earnings and revenue. The stock is currently ranked #1 (Strong Buy) by Zacks. Brainsway is part of the Zacks Medical - Products industry, alongside AtriCure (ATRC), which also saw a stock increase.
Product Stage
growth-positive
Wall Street Analysts Think Brainsway (BWAY) Could Surge 38.83%: Read This Before Placing a Bet
Brainsway Ltd. (BWAY) has seen a 5.9% increase in its stock price over the past four weeks, closing at $9.89. Analysts have set a mean price target of $13.73, suggesting a 38.8% upside potential. The price targets range from $12.50 to $16, with a standard deviation of $1.56, indicating a high level of agreement among analysts. Despite the potential upside, the article cautions investors about relying solely on price targets, as they can be misleading. Analysts often set optimistic targets due to business incentives. However, the consensus among analysts that Brainsway will report better-than-expected earnings supports a positive outlook for the stock.
growth-positive
Earnings Estimates Rising for Brainsway (BWAY): Will It Gain?
Brainsway Ltd. has shown a noticeable improvement in its earnings outlook, attracting positive attention from analysts and investors. The companys stock has been performing well, with a 5.9% increase over the past four weeks, driven by strong estimate revisions. Analysts have raised their earnings estimates for Brainsway, resulting in a Zacks Rank #1 (Strong Buy) rating. The company is expected to see significant year-over-year earnings growth, with estimates for the current quarter and full year showing substantial increases. This positive trend in earnings estimates suggests further potential upside for the stock, making it an attractive addition to investment portfolios.
growth-positive
New Strong Buy Stocks for January 14th
The article highlights five companies that have been added to the Zacks Rank #1 (Strong Buy) list, indicating a positive outlook for their stock performance. Brainsway, a medical device company, has seen a 60% increase in its earnings estimate over the last 60 days. Grupo Televisa, the largest media company in the Spanish-speaking world, has experienced a 22.2% increase in its earnings estimate. ICU Medical, Sally Beauty, and PHINIA Inc. have also shown significant growth in their earnings estimates. The article suggests that these companies are strong investment opportunities based on their recent performance and Zacks analysis.
growth-positive
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Brainsway Ltd. Sponsored ADR (BWAY) is currently outperforming its peers in the Medical group, which ranks #2 within the Zacks Sector Rank. The company has achieved a Zacks Rank of #2 (Buy) and has seen its full-year earnings estimate increase by 33.3% over the past 90 days. Since the start of the year, BWAY has returned about 44.3%, significantly outperforming the average loss of 3.8% in the Medical sector. The article also mentions Butterfly Network, Inc. (BFLY), another Medical stock with a strong performance, returning 188% year-to-date. Both companies are highlighted as potential solid performers in the Medical sector.
growth-positive
Brainsway reports independent pilot data on Deep TMS technology for AUD
BrainsWay announced positive results from a pilot study conducted at Stanford University, which evaluated the use of its Deep Transcranial Magnetic Stimulation (TMS) technology for treating alcohol use disorder (AUD). The study, published in the Brain Stimulation journal, demonstrated that patients receiving accelerated Deep TMS treatment showed significant improvements compared to other treatment methods. These improvements included reduced heavy drinking days, regular drinking days, and relapse rates. The promising results highlight the potential of BrainsWays technology in treating AUD, contributing to the companys growth prospects. Additionally, BrainsWays price target was raised by Ladenburg, reflecting confidence in its market performance.
growth-positive
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BrainsWay Ltd. announced positive pilot data from a study conducted at Stanford University using its Deep Transcranial Magnetic Stimulation (TMS) technology to treat alcohol use disorder (AUD). The study showed improved outcomes for patients treated with BrainsWays technology compared to traditional methods. Following the publication of the study, the U.S. National Institutes of Health awarded approximately $1.5 million to further explore the efficacy of BrainsWays Deep TMS system in treating substance use addictions. This development highlights the potential of Deep TMS as a noninvasive treatment for addiction disorders. The studys promising results suggest a significant step forward in treating AUD and other addictions, although the technology is not yet FDA-cleared for AUD treatment.
Investment
growth-positive
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced positive results from a clinical study evaluating the effects of deep transcranial magnetic stimulation (Deep TMS) on patients with peripheral neuropathic pain. The study, published in the Neuromodulation journal, involved a double-blind, randomized crossover trial with 17 patients. Results showed that active Deep TMS therapy significantly reduced pain intensity and improved symptoms of anxiety and depression compared to sham treatment. These findings add to the growing clinical evidence supporting Deep TMSs potential efficacy in treating various brain-related conditions. Although not yet FDA-cleared for neuropathic pain, BrainsWay aims to further explore these promising results through additional research.
growth-positive
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, reported a 26% year-over-year revenue growth for Q3 2024, with revenues reaching $10.5 million. The company raised its full-year revenue guidance to $40-41 million and achieved a net income of $0.7 million. BrainsWay secured $20 million in equity financing from Valor Equity Partners to support strategic initiatives. The company expanded its market presence by shipping 177 Deep TMS systems, a 12% increase from the previous year, and expanded access in the U.S. and East Asia. Additionally, the Israel Ministry of Defense approved reimbursement for Deep TMS therapy for PTSD patients. Dr. Richard Bermudes was appointed as the new Chief Medical Officer.
InvestmentExpandManagement ChangesCustomers
growth-positive
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
Brainsway Ltd. Sponsored ADR, a company in the Medical sector, has shown impressive stock performance this year, outperforming its peers. With a Zacks Rank of #2 (Buy), the companys full-year earnings estimate has increased by 111.1%, indicating improved analyst sentiment and a stronger earnings outlook. Year-to-date, Brainsways stock has gained approximately 53.6%, significantly higher than the average return of 4.2% for Medical companies. The company is part of the Medical - Products industry, which has seen a 14.8% gain this year. Brainsways performance is notable compared to another strong performer, Intuitive Surgical, Inc., which has also outperformed the sector. Investors interested in Medical stocks should keep an eye on both companies for continued solid performance.
growth-positive
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced it will release its Q3 2024 financial results on November 12, 2024. The company will host a conference call to discuss the results and provide updates on its operations. BrainsWay is known for its Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which has received FDA clearance for multiple indications, including major depressive disorder and obsessive-compulsive disorder. The company is conducting additional clinical trials to expand its treatment applications. Founded in 2003, BrainsWay operates from Burlington, MA, and Jerusalem, Israel, and is committed to increasing global awareness and access to its technology.
growth-positive
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 32.01%: Here's is How to Trade
The article discusses the recent performance and future prospects of Brainsway Ltd. (BWAY) stock, which has gained 24.2% over the past four weeks. Analysts have set a mean price target of $13.28, suggesting a potential upside of 32% from the current price of $10.06. Despite skepticism about the reliability of price targets, there is strong agreement among analysts about the companys improved earnings prospects, which could indicate further stock gains. The Zacks Consensus Estimate for the current year has increased by 4.2% over the past month, and BWAY holds a Zacks Rank #2 (Buy), placing it in the top 20% of ranked stocks. This suggests a positive outlook for the companys stock in the near term.
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway Ltd. Sponsored ADR (BWAY) has experienced significant stock growth, with shares rising 24.2% over the past month and reaching a 52-week high of $10.61. The company has consistently surpassed earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0 in its last earnings report on August 6, 2024. For the current fiscal year, Brainsway is projected to achieve a 123.08% increase in EPS and a 24.79% rise in revenues. The companys stock is currently trading at a premium compared to its industry peers, with a high Growth and Momentum Score. Brainsway holds a Zacks Rank of #2 (Buy), indicating potential for further growth. The Medical - Products industry, to which Brainsway belongs, is performing well, suggesting favorable conditions for continued success.
growth-positive
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Brainsway Ltd. Sponsored ADR, a company in the Medical sector, has shown impressive performance this year, outperforming its peers with a year-to-date return of about 44.9%, compared to the sectors average of 8.6%. The company holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook and improving analyst sentiment. The Zacks Consensus Estimate for Brainsways full-year earnings has increased by 177.8% in the past quarter. The Medical - Products industry, to which Brainsway belongs, has gained an average of 14.5% this year. Another notable performer in the Medical sector is Intuitive Surgical, Inc., with a year-to-date return of 44.5% and a Zacks Rank #1 (Strong Buy).
growth-positive
BrainsWay Expands Deep TMS Reach in East Asia
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, is expanding its presence in East Asia by deploying 15 Deep Transcranial Magnetic Stimulation (TMS) systems in Taiwan and South Korea. This strategic move highlights the companys success in these markets and supports its mission to improve mental health treatment globally. The expansion is driven by growing demand for BrainsWays innovative Deep TMS technology, which aims to enhance mental health care access worldwide.
Expand
growth-positive
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, announced the expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS) platform in East Asia. The company has placed 15 new systems in Taiwan and South Korea, indicating strong commercial success in this strategically important region. This expansion aligns with BrainsWays international growth strategy and highlights the increasing demand for its innovative Deep TMS platform. The company continues to focus on expanding access to its technology globally, supported by its international distribution partners. BrainsWay is committed to advancing neuroscience and improving health outcomes through its proprietary Deep TMS technology.
CustomersPartners
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway Ltd. Sponsored ADR (BWAY) has experienced a significant increase in its stock price, rising 30.3% over the past month and reaching a new 52-week high of $9.7. The company has consistently exceeded earnings expectations, reporting an EPS of $0.04 against a consensus estimate of $0 in its last earnings report on August 6, 2024. For the current fiscal year, Brainsway is expected to post earnings of $0.06 per share on $39.46 million in revenues, marking a substantial increase in both EPS and revenue. The companys strong performance is reflected in its Zacks Rank of #1 (Strong Buy) and a VGM Score of B, indicating potential for continued growth.
growth-positive
Does Brainsway (BWAY) Have the Potential to Rally 34.38% as Wall Street Analysts Expect?
Brainsway Ltd. (BWAY) has seen a significant stock price increase of 30.3% over the past four weeks, closing at $9.60. Analysts have set a mean price target of $12.90, indicating a potential 34.4% upside. The consensus among analysts suggests that the company will report better-than-expected earnings, contributing to a positive outlook for the stock. Despite skepticism about the reliability of price targets, the strong agreement among analysts and the companys Zacks Rank #1 (Strong Buy) suggest potential for further stock price growth. This optimism is supported by a 4.2% increase in the Zacks Consensus Estimate over the last 30 days.
growth-positive
Brainsway (BWAY) Soars 14.5%: Is Further Upside Left in the Stock?
Brainsway Ltd. experienced a significant stock price increase of 14.5% to $9.24 following a securities purchase agreement with an affiliate of Valor Equity Partners. This private investment financing is expected to generate gross proceeds of approximately $20 million, with a purchase price of $9.51 per share. The company is anticipated to report quarterly earnings of $0.02 per share, representing a 300% year-over-year change, and revenues of $9.9 million, up 19.3% from the previous year. The stock is currently rated as a Zacks Rank #1 (Strong Buy), indicating strong growth potential. The investment is seen as a positive development, contributing to the companys growth prospects.
Investment
growth-positive
BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
BrainsWay Ltd. announced a private investment financing agreement with Valor Equity Partners, expected to result in gross proceeds of approximately $20 million. The investment aims to strengthen BrainsWays balance sheet, advance strategic initiatives, and expand access to its Deep TMS technology. Valor, known for investing in high-growth companies, will provide expertise to help BrainsWay tap into new markets and revenue channels. The deal includes issuing American Depositary Shares and warrants, potentially increasing proceeds to $34.3 million if fully exercised. Valor will also gain board representation rights. The transaction is subject to shareholder approval.
Investment
growth-positive
BrainsWay Announces Significant Expansion on U.S. East Coast
BrainsWay Ltd. announced the expansion of its Deep TMS™ platform along the East Coast of the U.S. through an order of 14 new systems by a large mental health network. This order aligns with BrainsWays strategic goal of cultivating strong relationships with mental health groups and networks, supporting long-term profitable growth. As of June 30, 2024, BrainsWay had an installed base of 1,215 Deep TMS systems. The company is a global leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-clearance for multiple indications.
Customers
growth-positive
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced that the Israel Ministry of Defense’s Rehabilitation Department has approved reimbursement for its Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for PTSD patients in Israeli public hospitals. This approval is expected to help address the growing number of PTSD cases in Israel, particularly following recent conflicts. The company aims to expand this reimbursement to more medical centers and private clinics. This development is seen as a significant step in supporting PTSD patients and could facilitate further data collection to support additional applications. BrainsWay’s Deep TMS is not yet FDA-cleared for PTSD treatment.
Customers
growth-positive
Is Butterfly Network (BFLY) Outperforming Other Medical Stocks This Year?
Butterfly Network, Inc. (BFLY) has shown strong performance in the Medical sector this year, with a year-to-date increase of 39.8%, significantly outperforming the sectors average return of 11.7%. The company holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. Over the past 90 days, the consensus estimate for BFLYs full-year earnings has risen by 11.9%, reflecting improving analyst sentiment. The Medical Info Systems industry, to which BFLY belongs, has lost about 10.6% year-to-date, making BFLYs performance even more notable. Another outperforming stock in the Medical sector is Brainsway Ltd. Sponsored ADR (BWAY), which has seen a 17% increase year-to-date and holds a Zacks Rank of #1 (Strong Buy).
growth-positive
Here's Why Brainsway Ltd. Sponsored ADR (BWAY) is a Great Momentum Stock to Buy
The article discusses the momentum investing potential of Brainsway Ltd. Sponsored ADR (BWAY), highlighting its strong performance metrics. BWAY has a Momentum Style Score of A and a Zacks Rank of #1 (Strong Buy), indicating it is a solid momentum pick. The stock has shown significant price increases over various time frames, outperforming its industry and the S&P 500. Additionally, earnings estimates for BWAY have been revised upwards, further boosting its attractiveness. The article suggests that BWAY is well-positioned for near-term growth and recommends it as a promising investment.
growth-positive
BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments for mental health disorders, announced the appointment of Dr. Richard A. Bermudes as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Bermudes, a renowned clinician in the TMS field, brings over 20 years of experience in brain stimulation therapies and mental health technologies. He succeeds Dr. Aron Tendler, who will continue to collaborate on strategic research projects. This leadership change is expected to enhance BrainsWays clinical strategy and product development. BrainsWay is known for its Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which has FDA clearance for multiple indications.
Management Changes
growth-positive
Wall Street Analysts See a 60.85% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Shares of Brainsway Ltd. (BWAY) have gained 0.9% over the past four weeks, closing at $8.02. Analysts short-term price targets suggest a potential upside of 60.9%, with estimates ranging from $11 to $16. The consensus price target is $12.90, indicating strong agreement among analysts. Despite skepticism about the reliability of price targets, analysts optimism about BWAYs earnings prospects, reflected in a 166.7% increase in the Zacks Consensus Estimate for the current year, suggests potential growth. BWAY holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further indicating potential upside.
growth-positive
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
Brainsway Ltd. Sponsored ADR (BWAY) has been identified as a stock that is outperforming its peers in the medical group. The company is currently ranked #1 (Strong Buy) on the Zacks Rank, which emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. Over the past three months, the Zacks Consensus Estimate for BWAYs full-year earnings has moved 700% higher, indicating an improving sentiment among analysts. Since the start of the year, BWAY has returned about 17%, outperforming the average return of 10.1% for medical companies.
Investment
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
Shares of Brainsway Ltd. Sponsored ADR have been on the rise, with the stock up 21.1% over the past month and hitting a new 52-week high of $8.28. The company has a strong record of positive earnings surprises and is expected to post earnings of $0.06 per share on $39.46 million in revenues for the current fiscal year. For the next fiscal year, the company is projected to earn $0.13 per share on $45.32 million in revenues. Despite trading at a premium to the peer industry average, Brainsway currently has a Zacks Rank of #1 (Strong Buy), indicating potential for further gains.
Public Trading
growth-positive
Why Brainsway (BWAY) Might be Well Poised for a Surge
Earnings estimates for Brainsway Ltd. Sponsored ADR have been showing solid improvement lately, leading to a gain in the companys short-term stock price. Analysts growing optimism on the companys earnings prospects is driving estimates higher, which should get reflected in its stock price. The company is expected to earn $0.02 per share for the current quarter, which represents a year-over-year change of +300%. For the full year, the earnings estimate of $0.06 per share represents a change of +123.08% from the year-ago number. Brainsway currently carries a Zacks Rank #1 (Strong Buy).
Investment
growth-positive
Wall Street Analysts Think Brainsway (BWAY) Could Surge 72.29%: Read This Before Placing a Bet
Brainsway Ltd. Sponsored ADR (BWAY) has seen a 10.5% increase in its stock over the past four weeks, closing the last trading session at $6.82. Wall Street analysts have set short-term price targets for the company, with a mean price target of $11.75, indicating a 72.3% upside potential. The companys earnings prospects have also seen increasing optimism among analysts, with strong agreement in revising EPS estimates higher. The Zacks Consensus Estimate for the current year has increased 44.4% over the past month. BWAY currently has a Zacks Rank #1 (Strong Buy), indicating potential upside in the near term.
Investment
growth-positive
BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported a 28% year-over-year revenue growth in Q2 2024. The company also recorded positive quarterly net income for the third consecutive quarter and raised the lower end of its full-year 2024 revenue guidance to a range of $38.5 million to $40 million. BrainsWay shipped a net total of 114 Deep TMS™ systems during the first half of 2024, a 13% increase compared to the same period last year. The company also entered the Canadian market via an exclusive multi-year distribution agreement.
CustomersPartnersExpand
growth-positive
Strength Seen in Brainsway (BWAY): Can Its 9.3% Jump Turn into More Strength?
Shares of Brainsway Ltd. have rallied 9.3% in the last trading session, closing at $7.28. This is attributed to a higher volume of shares being traded than usual. The companys stock has been on the rise for the past three months, following a strong Q1 performance. The recent price rise is likely due to positive investor sentiment, which is expected to continue as the company prepares to report its Q2 earnings. Brainsway is expected to post break-even quarterly earnings per share in its upcoming report, a year-over-year change of +100%. Revenues are expected to be $9.4 million, up 20.1% from the year-ago quarter.
Investment
growth-positive
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.
Public Trading
growth-positive
BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold
BrainsWay Ltd. has signed an exclusive multi-year distribution agreement with a specialty distributor in Canada, marking a broad market entry for its Deep Transcranial Magnetic Stimulation (Deep TMS) system. The agreement includes minimum quantity orders, starting with 11 Deep TMS systems to be ordered in 2024. BrainsWays Deep TMS is currently cleared in Canada to treat major depressive disorder and obsessive-compulsive disorder. The agreement is expected to boost BrainsWays business and expand its global footprint.
PartnersExpand
growth-positive
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced its entry into the Canadian market. This expansion is facilitated through a multi-year exclusive distribution agreement with a specialty distributor. The agreement includes minimum quantity orders that increase over several years, starting with 11 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems to be ordered in 2024. BrainsWays Deep TMS system is currently cleared in Canada to treat major depressive disorder and obsessive-compulsive disorder.
PartnersExpand
growth-positive
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
BrainsWay Ltd. has initiated a clinical trial to evaluate a new accelerated treatment protocol for its Deep Transcranial Magnetic Stimulation (Deep TMS) system in treating major depressive disorder (MDD). The trial will enroll more than 100 patients diagnosed with MDD and divide them into two groups. One group will receive the novel accelerated treatment protocol over several treatment days, while the other will follow the FDA-cleared standard-of-care protocol over several weeks. The trial is currently underway at multiple sites across the United States.
InvestmentExpand
growth-positive
Small-Cap Standouts: 3 Stocks Destined to Rule Their Industries
The article discusses the potential of small-cap stocks, focusing on three companies: Aris Water Solutions, MoneyLion, and BrainsWay. Aris Water Solutions, a commercial water recycling business, recently received an upgrade from Citigroup, which predicts the stock will reach $18 per share. MoneyLion, a fintech company, has consolidated a sustainable customer base and has over 1,100 partnerships. BrainsWay, a business focused on mental health disorders, has shown potential with a 10-year compound annual growth rate of 35.09%. The author recommends considering these stocks for investment.
CustomersPartnersInvestment
growth-positive
BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced the initiation of a clinical trial to evaluate an accelerated treatment protocol for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat major depressive disorder (MDD). The trial will enroll over 100 patients with MDD, split into two groups. One group will receive the novel accelerated treatment protocol over several treatment days, and the other will receive the FDA-cleared standard-of-care protocol over several weeks. The trial aims to compare the outcomes achieved with the accelerated Deep TMS protocol versus the current standard-of-care Deep TMS protocol.
InvestmentExpand
growth-positive
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
BrainsWay Ltd. has received approval from the US Food and Drug Administration (FDA) to expand the use of its Deep Transcranial Magnetic Stimulation system (Deep TMS™) for the treatment of patients with major depressive disorder (MDD) aged 22 to 86. This is a change from the previous upper age limit of 68. This is the companys 10th FDA clearance and makes BrainsWay the first and only form of TMS indicated for the treatment of patients over the age of 68 suffering from MDD, including those with comorbid anxiety symptoms.
CustomersExpand
growth-positive
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 120.45%: Here's is How to Trade
Shares of Brainsway Ltd. have gained 3.5% over the past four weeks, closing the last trading session at $5.33. However, Wall Street analysts predict a potential upside of 120.5%, with a mean estimate of $11.75. The companys ability to report better earnings than previously predicted strengthens this view. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 133.3%. Brainsway currently has a Zacks Rank #2 (Buy), indicating potential upside in the near term.
Public Trading
growth-positive
BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights
BrainsWay Ltd. reported a 37% year-over-year revenue growth in Q1 2024, with revenues of $9.1 million. The company also recorded positive quarterly net income for the second consecutive quarter, and positive adjusted EBITDA and cash flow from operations for the third consecutive quarter. The company shipped a net total of 57 Deep TMS™ systems during the first quarter of 2024, a 24% increase from the same point in the prior year. The company also increased collaboration with existing partner, Katie’s Way Plus, which ordered an additional 18 Deep TMS systems.
CustomersPartners
growth-positive
BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The company will also host a conference call and webcast to discuss the results and provide an update on business operations. BrainsWay is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
Public Trading
growth-positive
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced the further expansion of access to its Deep TMS™ treatment in Israel. The company has installed 11 systems in the country recently, driven in part by a 45% increase in reimbursement rates. The company expects to install additional Deep TMS systems in Israel by the end of 2024. The expansion is part of the companys efforts to offer its therapy to mental health patients across Israel, especially in light of the rising mental health conditions in the country.
Expand
growth-positive
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
BrainsWay Ltd., a global leader in noninvasive neurostimulation treatments for mental health disorders, has published results from multiple trials exploring the efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS) as a potential treatment for Parkinsons Disease. The review, published in Frontiers of Human Neuroscience, summarizes data from six different studies involving 220 patients. The studies generally observed clinically meaningful improvements in motor symptoms, and in those studies which assessed non-motor symptoms, improvements in daily living and mood symptoms were reported. The company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence.
Customers
growth-positive
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
BrainsWay Ltd., a global leader in noninvasive neurostimulation treatments for mental health disorders, has announced positive results from a post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of late-life depression. The study, published in the Journal of Clinical Medicine, showed a 79.4% response rate and a 60.3% remission rate for patients aged 60-91 who had received at least 30 treatment sessions. The results are subject to further review by the FDA as BrainsWays existing FDA depression labeling does not extend to patients aged over 68.
CustomersExpand
growth-positive
After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)
Brainsway Ltd. Sponsored ADR (BWAY) has seen a significant decline in its stock price over the past four weeks, dropping by 13.6%. However, Wall Street analysts predict a potential trend reversal as the stock is now in oversold territory. The Relative Strength Index (RSI), a technical indicator, suggests that the heavy selling could be exhausting itself, indicating a potential rebound. Additionally, a strong agreement among sell-side analysts in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 84.5% over the last 30 days.
growth-positive
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced on March 18, 2024, that its significant existing partner, Katies Way Plus, has ordered an additional 18 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems. Katie’s Way Plus provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families. The expansion of this partnership will allow Katies Way Plus to grow to an extensive network of approximately 40 Deep TMS systems.
PartnersExpand
growth-positive
All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy
Brainsway Ltd. Sponsored ADR has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system is based on a companys changing earnings picture and is a powerful factor influencing near-term stock price movements. The rating upgrade for Brainsway reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. For the fiscal year ending December 2024, the company is expected to earn -$0.02 per share, a change of 84.6% from the year-ago reported number.
Investment
growth-positive
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
BrainsWay Ltd. has reported a 50% YoY revenue growth for Q4 2023, with revenues reaching $9.0 million. The company also reported positive net income for the quarter. For the full year 2024, the company expects revenues to be between $37-$40 million. During Q4 2023, the company shipped a net total of 60 Deep TMS™ new systems, increasing its total installed base to 1,101 systems, a 25% increase from the previous year. The company also expanded the availability of Deep TMS in South Korea and increased collaboration with a mental health treatment provider based in the Western region of the U.S.
CustomersExpand
growth-positive
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Brainsway is set to report its Q4 2023 results on March 6, with expectations of a diluted net loss of 1 cent per share, narrower than the Zacks Consensus Estimate of a loss of 7 cents per share. The company is expected to have remained resilient to the geopolitical turmoil in Israel, maintaining its supply of devices and keeping a contingency plan for alternative suppliers. Brainsway is also expected to have achieved its targeted breakeven operating income and positive adjusted EBITDA due to cost optimization measures. The company has expanded its Deep TMS technology in South Korea and the Western US, and is expected to have seen higher demand for OCD treatment indications.
CustomersPartnersExpand
Growth-Positive
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced that it will report its fourth quarter and full year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. BrainsWay is dedicated to leading through superior science and building on its unparalleled body of clinical evidence.
Investment
growth-positive
7 High-Growth Stocks to Snag for Spectacular Returns in 2024
The article discusses seven high-growth stocks that are expected to yield significant returns in 2024. These include StoneCo, which has seen a surge in total revenue and efficient scalability, and GigaCloud, which has seen growth in active buyers and average spending. Brainsways top-line growth is attributed to its neuromodulation technology, while Arch Resources operational performance suggests solid growth. Ambacs specialty property and casualty business, Everspan and Cirrata, have seen top and bottom-line growth. Forestars exceptional performance in Q1 2024 suggests sound business strategy and execution, and Celesticas outperformance in Q4 2023 is driven by the Connectivity & Cloud Solutions (CCS) segment.
CustomersExpand
growth-positive
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
The article discusses the potential growth of the biotechnology sector, highlighting three companies: Brainsway Ltd., United Therapeutics, and Vertex Pharmaceuticals. Brainsway is leading the global spread of Transcranial Magnetic Stimulation (TMS) solutions to treat neurological conditions and has plans to expand TMS in South Korea. United Therapeutics makes and commercializes innovative drugs that help solve cardiovascular issues and other infectious diseases worldwide. The company recently made a breakthrough with the successful transplant of an artificial heart. Vertex Pharmaceuticals is a biotechnology company with treatments ranging from sickle cell disease to cystic fibrosis. The company recently got FDA approval for a gene-editing therapy developed with CRISPR Therapeutics.
InvestmentExpand
growth-positive
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that it will be clinically evaluating an innovative stimulation technology in two new feasibility trials. The trials involve BrainsWay’s patented “Rotational Field” TMS, which enables activation of a greater number of neurons in the brain. The company aims to assess the potential clinical impact of this technology on patients in two newly launched feasibility studies. One study will test the technology in the field of rehabilitation following stroke, and another will test the technology in the field of obsessive-compulsive disorder.
InvestmentExpand
growth-positive
Recent Price Trend in Brainsway Ltd. Sponsored ADR (BWAY) is Your Friend, Here's Why
Brainsway Ltd. Sponsored ADR (BWAY) is identified as a suitable candidate for trend investors due to its solid price increase over a period of 12 weeks and its current trading at 95.9% of its 52-week High-Low Range. The stock currently carries a Zacks Rank #1 (Strong Buy), indicating it is in the top 5% of more than the 4,000 stocks that Zacks ranks based on trends in earnings estimate revisions and EPS surprises. The companys Average Broker Recommendation of #1 (Strong Buy) also confirms its fundamental strength.
Investment
growth-positive
Does Brainsway Ltd. Sponsored ADR (BWAY) Have the Potential to Rally 48.15% as Wall Street Analysts Expect?
Brainsway Ltd. Sponsored ADR (BWAY) has seen a 5% increase in its stock price over the past four weeks, closing the last trading session at $6.48. Wall Street analysts have set a mean price target of $9.60, indicating a potential 48.2% upside. However, the article warns against solely relying on this metric for investment decisions, as analysts ability to set accurate price targets has been questioned. The companys earnings prospects have seen increasing optimism among analysts, with strong agreement in revising EPS estimates higher. BWAY currently has a Zacks Rank #2 (Buy), indicating potential upside in the near term.
Public Trading
growth-positive
7 Under-the-Radar Stocks Gearing Up for a 2025 Breakthrough
The article discusses seven under-the-radar companies that are making significant strategic strides in their respective markets and are expected to have a breakthrough by 2025. These companies include Viper Energy, which is transitioning to a Delaware corporation and has acquired GRP; Concentrix, which is leveraging AI solutions across its operations; Ferroglobe, which has acquired a high-quality quartz mine; Intuitive Surgical, which has seen substantial growth in its digital tools; Roblox, which has grown across various age cohorts; ATI, which has seen a surge in demand for its products in the aerospace and defense sectors; and Brainsway, which has seen a significant surge in performance.
CustomersAcquisitionInvestmentExpand
growth-positive
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Brainsway Ltd. Sponsored ADR (BWAY) is outperforming its peers in the Medical sector, according to Zacks Investment Research. The companys year-to-date performance is significantly better than the sector average, with a return of 180.6% compared to the sectors average of -4.4%. The Zacks Consensus Estimate for BWAYs full-year earnings has increased by 39.9% in the past quarter, indicating an improved earnings outlook. The company currently has a Zacks Rank of #2 (Buy).
Investment
growth-positive
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced an increased collaboration with a growing mental health treatment provider based in the Western region of the United States. After a series of successive orders, BrainsWay’s most recent delivery will bring this provider’s installed base to a total of seven Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, with plans for additional expansion in the future. The Deep TMS system is currently FDA-cleared to treat major depressive disorder both with and without anxiety symptoms, obsessive-compulsive disorder (OCD), and smoking addiction.
CustomersExpand
Growth-Positive
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced an increased collaboration with a growing mental health treatment provider based in the Western region of the United States. The partnership has resulted in the installation of seven Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, with plans for further expansion. The Deep TMS system is FDA-cleared to treat major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction. BrainsWay is dedicated to increasing global awareness of and broad access to Deep TMS.
PartnersExpand
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
Brainsway Ltd. Sponsored ADR (BWAY) is identified as a solid choice for trend investing due to its strong price increase over a period of 12 weeks, gaining 28.9% over this period. The stock is currently trading at 83.4% of its 52-week High-Low Range, indicating potential for a breakout. The stock carries a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises. The companys Average Broker Recommendation is #1 (Strong Buy), indicating high optimism about the stocks near-term price performance.
Investment
growth-positive
Wall Street Analysts Predict a 68.72% Upside in Brainsway Ltd. Sponsored ADR (BWAY): Here's What You Should Know
Brainsway Ltd. has seen a 46.3% increase in its stock over the past four weeks, closing the last trading session at $5.69. Wall Street analysts have set a mean price target of $9.60, indicating a potential 68.7% upside. However, the article warns against relying solely on this metric for investment decisions, as analysts ability to set accurate price targets has been questioned. The companys earnings prospects are also looking positive, with the Zacks Consensus Estimate for the current year increasing 23.2% over the last 30 days. Brainsway currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by Zacks.
growth-positive
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
BrainsWay Ltd. has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. The company expects this development to meet the growing demand for advanced noninvasive neurostimulation treatments. The extended availability of this device is projected to increase its installed base in the country to more than 20 Deep TMS systems. This marks a significant milestone in the companys global expansion. The global neurostimulation device market is expected to reach $5.41 billion in 2022 and is projected to soar to $50.7 billion by 2030.
Expand
growth-positive
BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea
BrainsWay Ltd., a global leader in noninvasive neurostimulation treatments for mental health disorders, has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. The companys sales have been growing in the country, and it is expected to have over 20 Deep TMS systems installed there. The Deep TMS technology, which is used to treat major depressive disorder, is delivered through a patented coil design housed within a helmet. The system stimulates important neural networks in the brain.
ExpandCustomers
growth-positive
Brainsway Ltd. Sponsored ADR (BWAY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Brainsway Ltd. Sponsored ADR has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting an upward trend in earnings estimates. The Zacks rating system tracks the consensus measure of EPS estimates from sell-side analysts covering the stock for the current and following years. The rating upgrade for Brainsway reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The company is expected to earn -$0.28 per share for the fiscal year ending December 2023, a year-over-year change of 30%. Over the past three months, the Zacks Consensus Estimate for the company has increased 23.2%.
Investment
growth-positive
Market Mavericks: 3 Stocks That Could Turn $10K into $100K by 2027
The article discusses the potential for exponential growth in three companies: M-Tron, Brainsway, and ACM Research. M-Tron operates in specialized sectors and has a robust R&D pipeline, launching an average of 260 new products annually. The company has over 300 active customers and a backlog of $50.3 million as of Q3 2023. Brainsway focuses on collaborations with larger institutional and enterprise customers in the mental health industry. The company has a total installed base of 1,041 deep transcranial magnetic stimulation (TMS) systems as of Q3 2023. ACM Research aligns with China’s robust semiconductor industry growth and has a diverse product portfolio. The company has a judicious capital expenditure strategy, estimated at $75 million for 2023.
CustomersInvestmentExpand
growth-positive
Here's Why Momentum in Brainsway Ltd. Sponsored ADR (BWAY) Should Keep going
Brainsway Ltd. Sponsored ADR (BWAY) is identified as a suitable candidate for short-term trading due to its recent price strength and sound fundamentals. The stock has seen a price increase of 71.3% over a period of 12 weeks and 80.5% over the past four weeks, indicating a strong upward trend. BWAY is currently trading at 95.7% of its 52-week High-Low Range, suggesting a potential breakout. The stock carries a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises.
Investment
growth-positive
How Much Upside is Left in Brainsway Ltd. Sponsored ADR (BWAY)? Wall Street Analysts Think 50.27%
Brainsway Ltd. Sponsored ADRs stock has gained 66.5% over the past four weeks, closing the last trading session at $5.51. Wall Street analysts mean price target of $8.28 indicates a 50.3% upside potential. The company is expected to report better earnings than previously estimated, strengthening the view of a potential upside. However, investors are cautioned against making decisions solely based on price targets due to their questionable reliability. Brainsway currently has a Zacks Rank #1 (Strong Buy), indicating potential near-term upside.
Investment
growth-positive
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Blue Cross Blue Shield of Louisiana (BCBS of LA) has reduced the patient eligibility requirements for transcranial magnetic stimulation (TMS) treatment from four failed medication trials to two. This policy update aligns with the growing body of scientific evidence supporting the use of Deep TMS earlier in the treatment journey. The policy update will effectively reduce the barriers for treatment-resistant depression patients in gaining earlier access to BrainsWays technology.
CustomersPartners
growth-positive
BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced non-invasive treatment for brain disorders, reported a 61% year-over-year revenue growth in Q3 2023. The companys revenues were $8.3 million, a 61% increase compared to Q3 2022. The company also achieved positive adjusted EBITDA and cash flow from operations exceeding $1 million. BrainsWay secured a partnership with a prominent mental health clinical treatment provider in the Northeast U.S., which will result in 10 Deep TMS system installations in 2023. The company also received an order for an additional 10 Deep TMS systems from Katies Way Plus.
CustomersPartnersExpand
growth-positive
BrainsWay to Report Third Quarter 2023 Financial Results on November 15, 2023
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 15, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.
Customers
growth-positive
Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has received FDA clearance for its Deep TMS technology to treat smoking addiction. The Clinical TMS Society (CTMSS) has published the first coverage recommendations for smoking addiction treatment using TMS. BrainsWays Deep TMS is the only TMS technology to have received this clearance. The CTMSS has been instrumental in expanding TMS insurance coverage globally across multiple indications. The new coverage guidance recommends TMS coverage for individuals with a confirmed diagnosis of Tobacco Use Disorder who failed two alternative treatment methods.
CustomersExpand
growth-positive
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
AC Immune (ACIU) has been outperforming its peers in the medical sector, with a year-to-date return of 29.9% compared to the sectors average of -9.8%. The companys full-year earnings consensus estimate has also increased by 1.4% over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook. AC Immune is currently ranked #2 (Buy) by Zacks Rank. Another medical sector stock, Brainsway Ltd. Sponsored ADR (BWAY), has also outperformed the sector with a year-to-date return of 31.6%.
Investment
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression
Growth-Positive
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
AVROBIO, Inc. is outperforming its peers in the Medical sector, according to Zacks Investment Research. The companys year-to-date performance is significantly better than the average for Medical stocks, which have lost an average of 7.1% this year. AVROBIOs full-year earnings estimate has increased by 135.7% over the past 90 days, indicating improving analyst sentiment and a more positive earnings outlook. The company currently has a Zacks Rank of #2 (Buy). Another Medical stock, Brainsway Ltd. Sponsored ADR, has also outperformed the sector this year with a return of 72.5%.
Investment
growth-positive
BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced the acceptance and upcoming presentation of two Deep TMS posters at the World Congress of Psychiatry in Vienna, Austria. The posters present preliminary analysis of real-world results from Deep TMS patients and preliminary data from MDD patients treated with an accelerated Deep TMS treatment regimen. The results demonstrated high response and remission rates, comparable to those seen in younger patients. The companys research expands the understanding of Deep TMS and its potential ability to meet the treatment needs of a varying population of patients.
Customers
growth-positive
BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way Plus
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that its longstanding partner, Katie’s Way Plus, has ordered an additional 10 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems. This will more than double its existing offering. Katie’s Way Plus provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families. The additional systems will allow Katie’s Way Plus to extend its reach and offer hope to more individuals.
PartnersExpand
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
growth-positive
BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.
BrainsWay Ltd., a global leader in advanced non-invasive neurostimulation treatments, has announced a strategic partnership with a prominent mental health clinical treatment provider in the Northeast region of the United States. As a result of this partnership and a series of successive orders, a total of 10 Deep Transcranial Magnetic Stimulation (Deep TMS™) systems will be installed by this provider in 2023 alone, with the potential for additional systems thereafter. The partnership is expected to strengthen BrainsWays relationship with the mental health services provider and increase its traction with new institutional and enterprise customers in the U.S and internationally.
PartnersCustomersExpand
growth-positive
BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS
BrainsWay Ltd. is expanding the availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in Taiwan through a partnership with Unison Healthcare Group. This expansion aims to address the global mental health crisis and improve access to innovative mental health care. The collaboration with Unison Healthcare Group will enhance access and awareness of Deep TMS in Taiwan, particularly for individuals struggling with treatment-resistant mental health disorders. BrainsWay and Unison Healthcare Group have deployed 16 Deep TMS systems in Taiwan, with an additional five systems planned for installation. The global transcranial magnetic stimulation system market is projected to experience remarkable growth, presenting significant opportunities for companies like BrainsWay. BrainsWay shares have declined in the past year, but the company currently carries a Zacks Rank #2 (Buy).
CustomersPartners
growth-positive
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Align Technology, a company in the Medical sector, is outperforming its peers in terms of year-to-date returns. The companys earnings outlook has improved, and its stock has returned 69% so far this year, compared to the average return of -3.3% for Medical companies. Another Medical stock, Brainsway Ltd. Sponsored ADR, has also outperformed the sector with a 37.7% year-to-date return. Align Technology belongs to the Medical - Dental Supplies industry, while Brainsway Ltd. Sponsored ADR falls under the Medical - Products industry. Both stocks have a Zacks Rank of #2 (Buy). Investors interested in Medical stocks should pay attention to Align Technology and Brainsway Ltd. Sponsored ADR.
CustomersPartners
growth-positive
3 Stocks to Buy BEFORE They Become Wall Street Darlings
The article discusses three companies that are positioned for growth and are currently overlooked by investors. BrainsWay, a medical device disruptor, has shown growth in revenue and improved cost structure. Luminar Technologies, a leader in LiDAR technology, has announced collaborations and is on track to meet milestones. Crocs, a global footwear powerhouse, has achieved record revenues and expanded gross margins. The article suggests that these stocks have the potential for substantial upside in the future.
CustomersInvestment
growth-positive
BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in Taiwan. The company has partnered with Unison Healthcare Group to enhance access and awareness of Deep TMS in the Taiwanese market. Unison has been working closely with key hospitals, clinics, and thought leaders to ensure no patient suffers needlessly from a condition for which Deep TMS can provide a viable and efficacious treatment option. These efforts have resulted in an accelerated adoption of the technology and treatment across the country.
PartnersExpand
growth-positive
BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced non-invasive treatment for brain disorders, reported its second quarter 2023 financial results. The companys revenues were $7.8 million, an 18% increase compared to the first quarter of 2023. The company also expanded its Deep TMS technology platform in Western and Central U.S. and accelerated its international expansion in India. BrainsWays total Deep TMS installed base reached 985 total systems as of June 30, 2023, a 19% increase from the same point in the prior year. The company also appointed Ido Marom as Chief Financial Officer.
CustomersExpand
growth-positive
BrainsWay Announces Publication of Three New Deep TMS Research Publications
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals. The publications enhance understanding of the safety profile of TMS and its use in addressing smoking addiction and other substance use disorders. BrainsWays Deep TMS™ for smoking addiction is the only FDA-cleared TMS solution for any addiction. The company is committed to advancing the field of neuroscience through a greater understanding of this life-changing technology for mental health patients, their caregivers, and providers.
Customers
Growth-Positive
BrainsWay to Report Second Quarter 2023 Financial Results on August 9, 2023
BrainsWay Ltd., a global leader in noninvasive neurostimulation treatments for mental health disorders, has announced that it will report its second quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 9, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.
Investment
growth-positive
BrainsWay Accelerates International Expansion in India
BrainsWay Ltd., a global leader in noninvasive neurostimulation treatments for mental health disorders, has announced its expanded market penetration in India. This follows a series of multisystem orders from Asha Neuromodulation Clinics (ANC) and its affiliates, which will now own 25 Deep Transcranial Magnetic Stimulation (Deep TMS) systems. This move significantly increases access to BrainsWays patented technology for mental health patients in India suffering from conditions such as depression, OCD, and smoking addiction. The companys CEO, Hadar Levy, expressed satisfaction with the traction their therapy is gaining in India.
CustomersPartnersExpand
growth-positive
BrainsWay Announces Significant Expansion in Western and Central U.S.
BrainsWay has announced the order of 30 new Deep Transcranial Magnetic Stimulation (Deep TMS™) systems by a large TMS network of clinics in the Western and Central United States. The order includes systems for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). This partnership with the TMS network will significantly expand BrainsWays technology platform and improve access to their therapeutic solution. The TMS network has nearly 20 clinics across 6 states and offers cutting-edge technology and breakthrough treatments in psychiatry. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders and is committed to improving health and transforming lives.
Customers
growth-positive
BrainsWay Announces Appointment of Ido Marom as CFO
BrainsWay has announced the appointment of Ido Marom as Chief Financial Officer (CFO). Marom, an experienced senior financial leader, will succeed Scott Areglado. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is focused on strategically growing its business and gaining market share in the evolving TMS market. Maroms financial leadership experience is expected to be critical in achieving these goals. BrainsWay is dedicated to advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company has obtained three FDA-cleared indications for its treatments and is conducting additional clinical trials in various psychiatric, neurological, and addiction disorders.
Management Changes
growth-negative
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced non-invasive treatment for brain disorders, reported its first quarter 2023 financial results. The companys revenues were $6.6 million, a 10% increase compared to the fourth quarter of 2022. However, compared to the first quarter of 2022, the revenues decreased by 17%. The company shipped a net total of 48 Deep TMS new systems during the first quarter of 2023, bringing its total installed base to 932 systems. The company also reported a net loss of $2.4 million for the first quarter of 2023.
Customers
growth-positive
BrainsWay Launches Investigator Initiated Study (IIS) Program
BrainsWay has launched its Investigator Initiated Study Program to support further research on Deep Transcranial Magnetic Stimulation (Deep TMS™) by the clinical research community through data collaboration and equipment loan initiatives. The program aims to advance current knowledge about Deep TMS and will grant applications based on clinical and scientific significance, scope, innovation, and applicability. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders and is dedicated to improving health and transforming lives. The company has obtained three FDA-cleared indications for its Deep TMS technology and is conducting additional clinical trials in various psychiatric, neurological, and addiction disorders. BrainsWay is committed to increasing global awareness and access to Deep TMS.
PartnersExpand
Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023
growth-positive
BrainsWay to Participate in Clinical TMS Society and American Psychiatric Association Meetings
BrainsWay will be presenting new research on Deep TMS depression treatment at upcoming conferences. The company will participate in the Annual Meeting of the Clinical TMS Society and the Annual Meeting of the American Psychiatric Association. BrainsWay will present posters focusing on the efficacy of Deep TMS for treatment-resistant depression and its impact on quality of life. The companys participation in these conferences reflects the growing interest in Deep TMS technology among clinical psychiatrists and researchers. BrainsWays patented H-Coil technology, which is designed to penetrate deeper and broader structures of the brain, has been FDA-cleared for treating major depressive disorder since 2013. The company aims to advance neuroscience and improve mental health through its noninvasive neurostimulation treatments.
CustomersPartners
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights
BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award
BrainsWay Announces Appointment of Hadar Levy as CEO
BrainsWay Announces Appointment of Ami Boehm as New Chairman
New Strong Sell Stocks for February 1st
Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay
New Strong Sell Stocks for January 10th
BrainsWay Resolves Neuronetics Litigation
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom
growth-positive
BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
BrainsWay has launched a nationwide sweepstakes called Dont Miss Another Moment to raise awareness of its Deep TMS™ treatment for mental health disorders. The sweepstakes encourages people living with mental health conditions to seek help and not miss out on lifes precious moments. Participants can enter the sweepstakes by following or liking BrainsWays social media channels and sharing the Dont Miss Another Moment commercial. The winner will receive a $2,000 Airbnb gift card. The sweepstakes aligns with Depression Awareness Month and aims to reduce the stigma of seeking help for mental illness. BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders.
Customers
growth-positive
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
BrainsWays President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley, an event organized by the National Alliance on Mental Illness (NAMI) to increase mental health awareness and raise funds for programs. The event aligns with BrainsWays goal of raising awareness about mental illness and increasing access to mental health resources. The Silicon Valley Walk will take place on October 1, 2022. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology.
Partners
growth-positive
BrainsWay Receives New FDA Clearance for Treating Depression and Anxious DepressionDepression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Clearance | BioSpace
Brainsway Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Deep TMS H7 Coil, a noninvasive neurostimulation treatment for major depressive disorder and depression with comorbid anxiety symptoms. The clearance allows clinicians to provide more personalized medicine for their patients. The FDAs decision was based on successful results from a multicenter trial, which showed comparable efficacy rates for the H7 Coil and Brainsways H1 Coil. Brainsway plans to implement a training program to educate customers on using the H7 Coil for depression treatment. The companys commitment to research and development has solidified its leadership position in the field of noninvasive neurostimulation treatments. Major depressive disorder affects millions of people worldwide, and the economic burden in the United States is significant.
Customers
growth-positive
BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression
BrainsWay Ltd. announced that the Israeli Ministry of Health has approved coverage for its Deep TMS system for the treatment of depression. This means that the treatment will be available to qualifying patients free of charge. The coverage includes up to 40 treatment sessions to be administered in hospitals. BrainsWay sees this as a significant milestone and a key component of their growth strategy. They are committed to expanding insurance coverage in Israel and globally to increase access to their groundbreaking treatment.
Customers
growth-positive
BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™
Highmark Blue Cross Blue Shield has issued a positive coverage policy for the BrainsWay Deep TMS system for the treatment of obsessive-compulsive disorder (OCD). This coverage policy applies to 6.8 million Highmark BCBS members in four states. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The positive coverage policy brings the total number of lives eligible for Deep TMS OCD coverage to nearly 70 million. BrainsWay is the only TMS company to have obtained FDA clearance for the treatment of OCD based on positive clinical data from a pivotal study conducted on its own device. The company is dedicated to expanding OCD reimbursement and driving further positive coverage developments.
Customers
growth-positive
BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression
BrainsWay Ltd. has announced the publication of results in the Journal of Clinical Medicine that demonstrate the efficacy of its proprietary Deep TMS treatment in reducing anxiety symptoms in patients with depression. The study found that Deep TMS had a statistically significant and meaningful effect in reducing anxiety symptoms among depression patients. This supports the concept that Deep TMS can target areas in the brain associated with both anxiety and depression. The results of this publication further refine the understanding of the utility of Deep TMS in addressing comorbid anxiety symptoms. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders and is dedicated to increasing global awareness of and access to Deep TMS.
Customers
growth-positive
החברה שפיתחה קסדה לטיפול במחלות מוח מחכה לפריצת דרך
Brainsway, a company that has developed a helmet that creates deep brain magnetic stimulation for the treatment of neurological and psychiatric diseases, has been consistently reporting significant business progress in recent months. The company has received positive responses in the US regarding insurance coverage for its OCD treatment technology and has received several approvals to expand its treatment range for depression. The companys device is already installed in 771 clinics in the US, a 22% increase compared to the same period, but the market is still not saturated. The companys gross profitability is high, 78%, not far from the profitability of drug companies, and on the very high side of gross profitability in medical equipment.
CustomersExpand
growth-positive
BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported a 34% year-over-year revenue growth in Q3 2021. The company also received regulatory clearance for its Deep TMS System for the treatment of anxious depression. For the three and nine months ended September 30, 2021, revenues were $8.1 million and $21.2 million, respectively. The company also appointed Zafiris “Jeff” Daskalakis, a world-renowned brain stimulation expert, to its Scientific Advisory Board.
CustomersManagement Changes
growth-positive
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients
BrainsWay has received 510(k) clearance from the FDA to market its Deep Transcranial Magnetic Stimulation (Deep TMS™) System for the reduction of comorbid anxiety symptoms in adult patients with depression. This expands the companys depression indication and establishes its leadership position in the field. The FDA clearance allows BrainsWay to market its Deep TMS System for the treatment of depressive episodes and for decreasing anxiety symptoms in adult patients suffering from major depressive disorder. The clearance is based on data from 573 patients who underwent Deep TMS treatment in 11 studies, demonstrating consistent and clinically meaningful results. Comorbid anxiety symptoms are common in patients with major depressive disorder, and this new indication addresses a significant need in the market.
Customers
growth-positive
BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield® Licensee HCSC
BrainsWay has announced that Health Care Service Corporation (HCSC) has issued a positive coverage policy for the BrainsWay Deep TMS™ system for the treatment of obsessive-compulsive disorder (OCD). HCSC is the largest customer-owned health insurance company in the U.S., covering approximately 17 million members. This coverage policy is indicative of the strong reimbursement momentum that BrainsWay is experiencing for its Deep TMS treatment for OCD. The economic burden of OCD treatments on the U.S. healthcare system is estimated to be over $7 billion per year.
Customers
growth-positive
BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported its fourth quarter and full year 2020 financial results. The company saw a 17% increase in revenues for the three months ended December 31, 2020, compared to the third quarter of 2020, and a 12% increase from the fourth quarter of 2019. The company also successfully closed a follow-on equity offering in March 2021, raising $45.2 million of gross proceeds. The company plans to expand the number of U.S. sales territories it covers from 13 to 18.
Investment
growth-positive
BrainsWay aims to treat Covid-caused depression by "jumpstarting" brain
Israeli medical device company BrainsWay is gaining attention for its innovative method of treating neurological conditions such as depression and obsessive-compulsive disorder. The company uses a unique form of transcranial magnetic stimulation (TMS) to stream electrical currents to specific areas of the brain, providing healing and relief. BrainsWays TMS technology has a success rate of 70% for treating difficult patients who have not responded to other treatments. The coronavirus pandemic has increased the number of depressed individuals, particularly among 18-25 year olds. BrainsWays non-invasive and tolerable treatment offers an alternative to traditional methods. The company has received FDA clearance for treating smoking addiction and clearance in Europe for treating post-traumatic stress disorder (PTSD) and Parkinsons disease. BrainsWay is a publicly traded company on the Tel Aviv Stock Exchange since 2007.
Customers
growth-positive
BrainsWay Signs Exclusive Distribution Agreement with Gaelan Medical Trade LLC
BrainsWay has announced an exclusive distribution agreement with Gaelan Medical Trade LLC to supply its Deep Transcranial Magnetic Stimulation (Deep TMS) system in the United Arab Emirates (UAE). This agreement follows the recent Abraham Accords Declaration, which established economic ties between Israel, the UAE, and the United States. BrainsWays Deep TMS system is used for the treatment of brain disorders such as major depressive disorder and obsessive-compulsive disorder. The partnership with Gaelan, a member of the Ghassan Aboud Group, will expand access to this technology in the UAE and improve mental health in the region.
Partners
growth-positive
BrainsWay Reports Third Quarter 2020 Financial Results and Operational Highlights
BrainsWay Ltd., a global leader in non-invasive treatment of brain disorders, reported its financial results for Q3 2020. The companys revenues were $6.0 million, a 25% increase sequentially from Q2 2020, and a 1% increase from Q3 2019. BrainsWays Deep TMS installed base was 593 total systems, a 22% increase from the same period in 2019. The company also received 510(k) clearance from the U.S. Food and Drug Administration for its Deep TMS system for use as an aid in short-term smoking cessation in adults.
Customers
growth-positive
BrainsWay Announces Publication of New Real-World OCD Data for its Deep TMS System in Journal of Psychiatric Research
BrainsWay Ltd. has announced the publication of new positive data from a post-marketing study on their non-invasive medical device, Deep TMS, for the treatment of obsessive-compulsive disorder (OCD). The study showed that 58% of patients who completed the full course of therapy achieved a response, and 73% of patients demonstrated a response at least once during treatment. The study also demonstrated that the therapeutic effect from Deep TMS can be maintained for weeks. BrainsWay intends to leverage these compelling results to secure reimbursement for Deep TMS in OCD. OCD affects about 2.3% of the U.S. population, and the BrainsWay Deep TMS system provides a non-invasive treatment option for patients. The company received FDA clearance for the treatment of OCD in 2018.
CustomersInvestment
growth-positive
Jerusalem-based BrainsWay receives FDA clearance for magnetic stimulation system to help smokers quit
BrainsWay Ltd. has received FDA clearance for its deep transcranial magnetic stimulation (Deep TMS) system aimed at helping smokers quit. The companys Deep TMS technology has shown promising results in a large, randomized pivotal study. This FDA clearance marks the companys third cleared coil and indication. BrainsWay plans to release its newly cleared and proprietary H4 Deep TMS coil for smoking cessation early next year. The companys CEO expressed confidence in the technologys ability to increase the continuous quit rate among smokers. This FDA clearance solidifies BrainsWays position as an industry leader in developing innovative therapeutic solutions.
Customers
growth-positive
BrainsWay Launches New Website to Enhance Mental Health Awareness
BrainsWay Ltd., a global leader in noninvasive treatment of brain disorders, has launched its newly redesigned website. The site offers easy access to mental health resources for patients and healthcare professionals. The company aims to provide education and raise awareness about mental health, specifically major depressive disorder and obsessive-compulsive disorder. The website will be regularly updated with new resources, latest research, and a locator for local Deep Transcranial Magnetic Stimulation providers.
CustomersExpand
growth-positive
BrainsWay Strengthens Senior Leadership Team with Appointment of Christopher Boyer as Vice President of Global Marketing
BrainsWay Ltd., a global leader in non-invasive treatment of brain disorders, has announced the appointment of Christopher Boyer as Vice President of Global Marketing. Boyer will be responsible for worldwide marketing activities, expanding BrainsWay’s market share, leading the corporate go-to-market strategy, and overseeing the continued development of the BrainsWay brand. He brings over 15 years of medical device marketing and business development experience to the role. The company hopes to leverage his experience to continue growing the demand for their Deep Transcranial Magnetic Stimulation (Deep TMS) system in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
Management Changes
growth-positive
BrainsWay Enhances Senior Leadership with Promotion and New Executive Addition
BrainsWay Ltd. has announced the promotion of Hadar Levy to Senior Vice President and General Manager of North America, and the appointment of Judith Huber as Senior Vice President and Chief Financial Officer. Levy will oversee BrainsWays North American business, while Huber will lead the companys financial operations. Levy has been with the company for nearly six years and has contributed to its strong growth. Huber brings over 30 years of experience in strategic and financial planning to the role. The company aims to further accelerate commercialization and market adoption of its Deep Transcranial Magnetic Stimulation system.
Management Changes
growth-positive
BrainsWay Launches #StandAgainstTheStigma Campaign to Promote Mental Health Awareness Month
BrainsWay has launched a sweepstakes campaign called #StandAgainstTheStigma to raise awareness about mental health. The campaign encourages people to share their stories and experiences with mental illness. For every entry, BrainsWay will donate $1 to the Coronavirus Mental Health Fund created by the National Alliance of Mental Illness (NAMI). The companys Deep TMS treatment, which is FDA-cleared for patients with treatment-resistant depression and obsessive-compulsive disorder, is highlighted in the campaign. BrainsWay aims to foster conversations around mental health and increase awareness of available resources and treatments. The campaign is expected to have a positive impact on the companys growth.
CustomersPartners
growth-positive
BrainsWay Announces Positive Data from Smoking Cessation Multicenter Study Evaluating Use of Deep TMS at Society for Research on Nicotine & Tobacco 2020
BrainsWay presented positive data from its multicenter study on the use of its proprietary Deep TMS system for smoking cessation. The study showed promising results, with a higher continuous quit rate among participants who received Deep TMS treatment compared to the control group. BrainsWay aims to make Deep TMS available as a treatment option for smokers looking to quit. The company is a global leader in non-invasive brain stimulation for addiction and also focuses on the treatment of major depressive disorder and obsessive-compulsive disorder. The study was presented at the Society for Research on Nicotine & Tobacco annual conference. The impact on the company is growth-positive as it demonstrates the effectiveness of its technology in a new application.
Customers
growth-positive
BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System in the treatment of Adults with ADHD
BrainsWay Ltd. has announced positive results from a clinical trial assessing the efficacy of its proprietary H6-coil deep transcranial magnetic stimulation (dTMS) System for the treatment of adults with attention deficit hyperactivity disorder (ADHD). The trial showed a statistically significant improvement in patient-reported assessments of inattention, along with increased activity in the dorsolateral prefrontal cortex (DLPFC), a brain area associated with ADHD. The study enrolled 75 adults with ADHD and used functional magnetic resonance imaging (fMRI) to assess the effect of dTMS on clinical, cognitive, and neural activity. BrainsWays dTMS technology has previously been FDA cleared for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
Customers
growth-negative
BrainsWay share price up despite PTSD trial failure
Brainsway Ltd.s H7-coil deep transcranial magnetic stimulation (dTMS) system failed to demonstrate effectiveness in treating adults with post-traumatic stress disorder (PTSD) in a trial. The company will not continue the current trial but may conduct later trials with different endpoints. Despite the trial results, Brainsways share price increased on the Tel Aviv Stock Exchange and Nasdaq. The company has already achieved success in trials for depression, obsessive-compulsive disorder (OCD), and smoking addiction. Brainsways treatment method is also being tested for other disorders. The potential market for the companys products is in the billions of dollars. Brainsways revenue in the last quarter was $5.9 million, with a net loss of $2.6 million.
CustomersInvestment
growth-positive
Greenbrook TMS NeuroHealth Centers Now Offer BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) for Obsessive-Compulsive Disorder (OCD) at Two Locations in St. Louis, Missouri
Greenbrook TMS NeuroHealth Centers is now offering BrainsWays Deep TMS Therapy for obsessive-compulsive disorder (OCD) in the St. Louis area. The company has already been treating patients with major depressive disorder (MDD) using Deep TMS. BrainsWays Deep TMS is a medication-free and noninvasive treatment that targets deep structures of the brain to alleviate OCD symptoms. Greenbrook TMS NeuroHealth Centers is a leading provider of TMS treatment for depression, OCD, and other mental illnesses. The company operates 122 treatment centers across the United States.
Customers
growth-positive
BrainsWay Announces Successful Results in Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as an Aid in Smoking Cessation
BrainsWay Ltd. has announced final positive results from its pivotal multicenter trial assessing the safety and efficacy of its H4 Deep transcranial magnetic stimulation system (Deep TMS) as an aid in smoking cessation. The trial represents the first multicenter pivotal study conducted with any non-invasive brain stimulation device in the addiction space. The results showed a significant improvement in the continuous quit rate and a reduction in the number of cigarettes smoked. BrainsWay intends to meet with the FDA to discuss regulatory submission and potential clearance pathway. The company sees smoking cessation as a significant market opportunity for Deep TMS and is optimistic about the potential for using their platform technology to treat other addictions as well.
Customers
growth-negative
BrainsWay CEO to Step Down
BrainsWay Ltd. announced the resignation of its CEO Yaacov Michlin. The companys board of directors plans to appoint a new U.S.-based CEO. In the meantime, co-founder David Zacut will serve as interim CEO. BrainsWay develops headsets that use magnetic stimulation to treat brain disorders and completed its IPO on Nasdaq in April, raising $27.5 million.
Management Changes
growth-positive
BrainsWay touts results of dTMS study for depression
BrainsWay has touted the results of a study showing that deep transcranial magnetic stimulation (dTMS) combined with standard medication is more effective at reducing depression levels in major depressive disorder (MDD) patients than medication alone. The study was conducted independently by researchers in Croatia and the results were published in the Journal of Psychiatric Research. The study found that both the dTMS group and the standard TMS group had significantly higher remission rates compared to the control group. BrainsWay is currently conducting clinical trials for the use of dTMS in other disorders and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS), and post-stroke rehabilitation.
CustomersExpand
growth-positive
New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay's Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder
BrainsWay Ltd. has announced new data from a clinical trial demonstrating the effectiveness of its Deep TMS System in treating Obsessive Compulsive Disorder (OCD). The trial showed that the non-invasive treatment achieved a 45% response rate among patients after one month of follow-up, with significantly reduced symptoms compared to a placebo. The Deep TMS system provides a personalized treatment option for OCD patients, augmenting existing therapeutic approaches. The results of the trial suggest that Deep TMS can provide a measurable benefit to OCD patients who struggle with debilitating symptoms despite receiving the best available drug treatments. The treatment received FDA clearance in August 2018 and is the only TMS platform cleared to treat OCD. The study was published in the American Journal of Psychiatry.
Customers
growth-positive
BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder
BrainsWay Ltd. has announced the shipment of the 100th Deep TMS helmet for the treatment of obsessive-compulsive disorder (OCD) in adults. The companys Deep Transcranial Magnetic Stimulation system (Deep TMS) technology is the only TMS product currently available for OCD patients. The shipment of OCD helmets to 100 locations across the U.S. allows BrainsWay to access a large and growing number of patients in need of a non-invasive, safe, and effective treatment option. The milestone represents substantial physician demand for additional treatment options for patients with OCD.
Customers
growth-positive
BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment
BrainsWay has reached target recruitment for its multicenter study on the safety and efficacy of its deep transcranial magnetic stimulation system for smoking cessation. The study aims to provide a non-invasive, safe, and effective solution for chronic smoking addiction. BrainsWays Deep TMS device stimulates specific brain regions associated with addiction. The company has enrolled over 260 participants and expects to receive final results in Q4 2019. A preliminary study showed promising results in reducing cigarette consumption and nicotine dependence. BrainsWay is a medical device company focused on non-invasive neuromodulation products for the treatment of major depressive disorder and obsessive-compulsive disorder.
Customers
growth-positive
Brainsway Completes Nasdaq IPO With $27.5 Million
Israeli medical device company Brainsway Ltd. has completed its initial public offering (IPO) on Nasdaq, raising $27.5 million. Brainsway develops headsets that use magnetic stimulation to treat brain disorders. The company began trading on Nasdaq last week.
Public Trading
growth-positive
Brainsway to Start Trading on Nasdaq Wednesday
Israeli medical device company Brainsway Ltd. plans to raise $27.5 million in its initial public offering (IPO) on Nasdaq. Brainsway develops headsets that use magnetic stimulation to treat brain disorders. The IPO is expected to close on April 22, with the option for underwriters to purchase additional shares within 30 days. The company was founded in 2003 and has offices in Jerusalem and the U.S.
Public Trading
growth-positive
BrainsWay raising $30m on Nasdaq
Israeli medical devices company Brainsway Ltd. has announced its first Nasdaq financing round. The companys magnetic helmet is used for the treatment of depression and OCD, and is being tested for recovery from smoking addiction. Brainsway has gained marketing approval and is experiencing growth in revenue. The companys revenue totaled $16.3 million in 2018, a 46% increase from the previous year. Brainsway is now focusing on leasing systems and regular usage fees as its business model, which has led to a climb in revenue. The company is also developing its product for other brain indications.
Investment
growth-positive
BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio
BrainsWay Ltd. has acquired a multi-channel transcranial magnetic stimulation (TMS) patent portfolio from TMS Innovations and entered into an exclusive option agreement with Stanford University for additional multi-channel TMS-related patents. BrainsWay is developing a next-generation multi-channel TMS stimulator that could provide more effective and flexible treatment options for brain disorders. The acquisition of the patent portfolio diversifies and reinforces BrainsWays existing patent portfolio in the field of multi-channel TMS. The companys Deep TMS system is FDA cleared for the treatment of major depressive disorder and recently received FDA clearance for the treatment of Obsessive Compulsive Disorder. BrainsWay aims to develop a cutting-edge TMS therapy that allows greater flexibility in treating multiple psychiatric and neurological indications.
AcquisitionPartners
growth-positive
BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: - "BrainsWay OCD Launchpad to Success"
BrainsWay Ltd. has announced the initiation of the Launchpad to Success program, which aims to support physicians in introducing patients to the companys deep transcranial magnetic stimulation (dTMS) system for the treatment of Obsessive-Compulsive Disorder (OCD) in adults. The program includes consulting and reference materials, patient generation resources, and a 90-day hands-on practice development. BrainsWays Deep TMS technology received FDA clearance for the treatment of OCD in adults in August 2018. The company is installing BrainsWay OCD as an upgrade of its current systems and as part of new installations. OCD affects more than two million adults in the U.S. and is difficult to treat with existing options. BrainsWay aims to provide physicians with the necessary support to successfully treat OCD patients.
Customers
growth-positive
BrainsWay Expands its Deep TMS Commercial Footprint into Asia Pacific
BrainsWay Ltd., a global leader in the advanced non-invasive treatment of brain disorders, has entered an exclusive distribution agreement with With Healthcare, a leading distributor of medical devices, to market BrainsWay’s Deep Transcranial Magnetic Stimulation System (Deep TMS) in South Korea. With Healthcare will be responsible for all sales, marketing and commercial activities related to Deep TMS in South Korea. This agreement follows recent distribution agreement for Deep TMS in Thailand and agent agreements in Singapore and India.
PartnersExpand
growth-positive
BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder
BrainsWay Ltd.s Deep TMS System has been approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of Major Depressive Disorder (MDD). The approval allows the company to market its product throughout Japan. The approval was obtained in collaboration with BrainsWays exclusive distributor in Japan, Century Medical, Inc. The PMDA approval is a significant milestone for BrainsWay as it expands its commercial footprint globally. The company sees Japan as a significant market opportunity and aims to provide its therapeutic solution to the many patients suffering from MDD in the country. The PMDA approval is also a precondition for receiving reimbursement coverage under the Japanese National Health Insurance Plan.
Customers
growth-positive
Brainsway files for $30m Nasdaq offering
Israeli medical devices company Brainsway Ltd. has filed a public prospectus for a Nasdaq offering to raise at least $30 million. The company has developed a magnetic helmet for the treatment of neurological diseases. Brainsways market cap is NIS 357 million. The companys share price fell 3% following the announcement of the prospectus. The US government shutdown may delay the offering, but the company can revise its prospectus if necessary. Brainsway has seen a 54% increase in revenue in the first nine months of 2018, attributed to a change in business model. The company is still posting an operating loss, but it has a higher backlog of expected revenue.
InvestmentPublic Trading
growth-positive
Brooklyn Minds Now Treats Obsessive-Compulsive Disorder Patients with Transcranial Magnetic Stimulation (Deep TMS)
Brooklyn Minds, a mental health facility, announced that it is now offering BrainsWays Deep Transcranial Magnetic Stimulation therapy for Obsessive-Compulsive Disorder (OCD). The facility has been using Deep TMS for depression since 2016 and has seen positive treatment responses. The therapy has been effective in reducing depressive symptoms and achieving full remission. Brooklyn Minds has provided over 4,000 customized treatments to date and offers various mental health services. BrainsWay is engaged in the research, development, and sales of a medical system for non-invasive treatment of brain disorders.
Customers
growth-positive
BrainsWay Announces First Shipments of Deep Transcranial Magnetic Stimulation Helmets for the Treatment of Obsessive-Compulsive Disorder
BrainsWay Ltd. has completed the first shipment of its Deep TMS system for the treatment of obsessive-compulsive disorder (OCD) in adults. The company has sent the helmets to twenty sites across the U.S., providing a new non-invasive treatment option for OCD patients. BrainsWays Deep TMS system is designed to stimulate deep and broad brain regions, targeting previously unreachable areas of the brain. OCD affects over 2 million adults in the United States and is difficult to treat with current options. BrainsWays treatment aims to provide a better quality of life for OCD patients. The company plans to ship more helmets to additional locations across the nation.
Customers
growth-positive
BrainsWay Receives First Ever FDA Clearance of a Non-Invasive Device for Treatment of Obsessive-Compulsive Disorder
BrainsWay Ltd. has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults. This represents the first ever non-invasive medical device clearance for the treatment of OCD. The clearance provides BrainsWay with a significant market opportunity, as there are more than two million U.S. adults suffering from OCD. BrainsWays Deep TMS technology can directly stimulate areas of the brain at a greater depth and breadth than any other TMS device on the market, allowing it to effectively treat OCD. The clearance was based on a pivotal, multicenter study that demonstrated statistically significant improvement in OCD symptoms severity for patients treated with Deep TMS compared to sham treatment.
Customers
growth-positive
Frost & Sullivan Publishes Update Coverage Report on Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising;target price unchanged.
Brainsway Ltd., an Israeli medical device firm, reported revenues of $3.6 million in the first quarter of 2018, with significant growth compared to the corresponding quarter in 2017. The companys operating loss decreased slightly, and it has a cash balance of $15.4 million. Brainsway also received FDA approval for marketing its system in the US with a new stimulator. The companys valuation is $129.5 million, and it entered into a private placement agreement with leading investment parties in Israel. Brainsway focuses on the development and commercialization of an H-coil helmet device for Deep Transcranial Magnetic Stimulation (dTMS).
InvestmentCustomers
growth-positive
Brainsway and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder
Brainsway Ltd. has announced a research collaboration with Cohen Veterans Bioscience and Stanford University School of Medicine to identify potential biomarkers in patients suffering from Post Traumatic Stress Disorder (PTSD). The collaboration involves the collection and analysis of electroencephalogram (EEG) data from patients enrolled in Brainsways ongoing multicenter PTSD trial. The analysis will be conducted by Stanford researchers and is expected to lead to the discovery of unique biomarkers in specific groups of PTSD patients. This personalized approach could improve treatment outcomes by guiding patients towards the most effective treatment options. Brainsways CEO, Yaacov Michlin, expressed excitement about the collaboration and the potential implications for their Deep Transcranial Magnetic Stimulation (dTMS) treatment. Cohen Veterans Biosciences Chief Medical Officer, Dr. Allyson Gage, highlighted the importance of developing a precision medicine approach to treat trauma-related brain disorders.
Partners
growth-positive
American Psychiatric Association
The article discusses various topics related to psychiatry and mental health, including the impact of engaging with communities to improve mental health care, the role of psychiatry specialists in addressing burnout, the potential role of beta blockers and melatonin in treating psychiatric illness-related sleep, and the interplay of substance use disorder and pain in patients. The article also highlights the need for improved screening and care for dementia and Alzheimers disease, the use of ketamine and esketamine in psychiatry, and the challenges in defining and treating mental illnesses. The events described in the article occurred on various dates in May and June 2022.
Expand
growth-positive
Brainsway raises $8.5m
Brainsway Ltd. has raised NIS 30 million ($8.5 million) from Israeli financial institutions. The company is awaiting a response from the FDA regarding its application for marketing approval for its magnetic stimulation helmets for the treatment of obsessive-compulsive disorder (OCD). If approved, it will be the first medical device in the market for this condition. The funding round makes it less likely that the company will seek a Nasdaq listing in the near future. Brainsway had $7.5 million in revenue in the first nine months of 2017 from its product for the treatment of depression. The company has a market cap of NIS 245 million and had $6 million in cash as of the end of the third quarter.
Investment
growth-positive
US Navy buys Brainsway helmets for treating depression
The US Navy will start using Brainsways deep TMS helmets for the treatment of depression at some of its healthcare centers. This marks an important stepping stone for Brainsway into the US market. The companys deep TMS helmets use magnetic pulse energy to stimulate deep structures of the brain and regulate electrical activity. Brainsways device has already been installed in therapeutic settings in multiple countries. The core technology was developed by Israeli scientists, and the company was established in 2003. Brainsways CEO is focused on expanding the companys strategic presence in the US and increasing sales there.
CustomersPartners
growth-positive
Brainsway data presentation boosts share price
Brainsway Ltd. released updated data about its commercial, clinical, and marketing operations. The companys share price increased by 5.4%. They have installed 101 Deep Transcranial Magnetic Stimulation devices worldwide and have orders for 36 more. The company plans to broaden its service to include new areas in Latin America, Japan, and Australia. They have FDA approval for their depression-treatment service and are covered by the insurance policies of 193 million people in the US. Brainsway aims to implement a new strategy to penetrate the US market, launch sales in Brazil, receive regulatory approval in Brazil, gain CE approval for additional clinical indications, and continue with commercial installations.
CustomersExpand
growth-positive
Brainsway rises on clinical trial success
Brainsway Ltd. reported success in a clinical trial for its Deep TMS treatment for Parkinsons disease. The trial included 60 patients, and the results showed significant clinical improvement among the patients. Brainsways share price rose 4.8% following the announcement.
Customers
growth-positive
Yelin Lapidot takes stake in Brainsway
Brainsway Ltd. has raised NIS 41 million in a private placement with Yelin Lapidot Investment House Ltd. The investment will be used to expand the market and consolidate the Deep TMS paradigm as the leading technology in the global neuropsychiatric market. Brainsway has recently leased and installed its Deep TMS system for the non-invasive treatment of neurological disorders at several medical institutions in the US.
Investment
growth-positive
Brainsway leases system to Harvard center
Brainsway has leased a Deep TMS system to Harvard Universitys McLean Hospital. The leasing agreement is a critical support and vote of confidence in Brainsways products by one of the worlds leading psychiatric hospitals. Brainsway also announced positive results in a final study of Deep TMS for the treatment of schizophrenia. All patients who completed the study showed clear improvement in the negative effects of the disease. The article was published on February 26, 2014.
Customers
growth-positive
Brainsway raises NIS 16m
Brainsway Ltd. has raised NIS 16 million from an allotment of shares and warrants to a group of investors led by Shavit Capital Fund LP. The company has the right to raise up to an additional NIS 3.75 million from additional investors. The investment is expected to support the companys progress towards obtaining FDA approval for its treatment for serious depression. Brainsways share price fell slightly following the announcement.
Investment
Brainsway Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 135 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Brainsway Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 101/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 513890764 |
| Crunchbase | brainsway |
| Phone | +97225813140 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-01-08T00:00:00.000Z |
| Created | 2014-07-23T00:00:00.000Z |
| Status detail | Public on TASE on Jan, 2007<br>Public on NASDAQ on Apr, 2019<br> |